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ABSTRACT 
 
OUTCOMES ASSOCIATED WITH THE UTILIZATION OF ANTIDEPRESSANTS 
AND PSYCHOTHERAPY AMONGST CANCER PATIENTS WITH DEPRESSION 
By Purva N. Parab, B. Pharm 
  
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2018 
Advisor: Pramit A. Nadpara, Ph.D. 
Assistant Professor, Department of Pharmacotherapy & Outcomes Science 
 
Objective: To determine patterns of use, prescription medicine costs, office-based visit costs 
and quality of life (QOL) across classes of antidepressants/psychotherapy in elderly cancer 
patients. Methods: Medical Expenditure Panel Survey data files from 2005-2015 for cancer 
patients with depression aged 18 years or older were used for the study. Frequencies of patients 
under specific classes of antidepressants/psychotherapy were identified. Costs and QOL scores 
were compared using Analysis of Variance (ANOVA). Generalized linear models, 
linear/multinomial logistic regression were used for analyses adjusted for demographics, overall 
health status, number and type of comorbidities. Results: The study sample consisted of 17,671 
cancer patients with depression. 32.08% patients had an antidepressant prescribed whereas 
15.30% reported psychotherapy. SSRI (62.44%) was the most frequently prescribed class. The 
prescription and office-based visits costs were adjusted for demographics, overall health status, 
number and type of comorbidities. These adjusted prescription costs were the highest for SNRI 
(Mean = $112.92), adjusted office-based (psychotherapy) visit costs were the highest for those 
receiving psychotherapy only without any antidepressant (Mean = $166.39/visit). QOL scores 
were higher amongst patients who had combinations of antidepressants prescribed, specifically 
SSRI with either a TCA or SNRI as compared to those who were prescribed an individual class 
or those who did not receive any treatment at all. Conclusion: Antidepressants were prescribed 
more often than psychotherapy amongst cancer patients with depression in the United States. 
xiii 
 
The prescription costs and associated QOL scores were higher amongst those with 
antidepressants prescribed as compared to those receiving psychotherapy with or without an 
antidepressant for cancer patients with depression in the United States.
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CHAPTER I: INTRODUCTION 
Section 1.1: Background 
 
Cancer is one of the most prevalent diseases in the country. In 2014, there were an estimated 
14,738,719 people living with cancer of any site in the United States (US) and it was estimated 
that there would be 1,688,780 new cancer cases in 2017.1 It has been listed as one of the priority 
conditions by the Agency for Healthcare Research and Quality (AHRQ).2 The mean survival 
rate of cancer patients was around 67% as per 2007-2013 data.1  Breast cancer is the most 
common type of cancer with more than 255,000 new cases expected in the United States in 
2017. The next most common types of cancers are lung and prostate cancer.1 Cancer patients 
have a reduced quality of life (QOL). This could be due to treatment side effects, disability or 
mental disturbance.3 There are also certain sociodemographic factors such as gender, marital 
status, income or job status that affect the mental well-being and thus QOL of cancer patients.3  
Patients who are over 65 years of age have an even more reduced QOL as compared to younger 
patients.4 
  The AHRQ estimates that the direct medical costs for cancer in the US in 2014 
were $87.7 billion. 58% of this cost was for hospital outpatient or doctor office visits whereas 
27% of this cost was for inpatient hospital stays.5 Thus, it can be seen from these figures that 
majority of cancer costs are associated with outpatient and physician office visits. Figure 1 
below summarizes the major sources of payment for total annual costs of cancer patients for the 
year 2014.  As seen from the figure, the total share of out of pocket costs for all the cancer 
patients in 2014 was $3.9 billion.5 On an average, cancer patients pay around $2116 to $8115 
out of pocket annually. One in ten patients reported that the costs amounted to at least 63% of 
their annual income.5 The financial burden on cancer survivors is thus high.6 The QOL of cancer 
patients depends highly on the financial burden, mainly out of pocket costs of cancer patients 
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along with the cancer treatment provided.6,7 Cancer survivors with increased financial burden 
have significantly lower physical and mental component scores and have higher odds of 
reporting depressed mood.6 QOL and financial burden of cancer patients are thus correlated and 
could depend on a lot of factors including the comorbidities involved.6,8 
 
 
a-Total patient out of pocket costs per year = $3.9 billion 
Other* - Employer’s Insurance, Tricare, Veteran’s Insurance and other state and local 
government insurance 
Figure 1: Sources of payment for total costs of cancer patients in the US per year 2014 
 
Cancer and comorbidities: 
 Past literature suggests that, cancer has common risk factors with various other 
conditions and hence has several comorbidities associated.8 Diabetes mellitus, chronic 
infections, diseases of the immune system and psychosocial disorders are some of the commonly 
identified comorbidities along with cancer.8 The impact of such comorbidities tends to be greater 
for cancers with a better prognosis, since otherwise the patients are more likely to die from their 
cancer regardless of other comorbidities associated.9 These comorbidities reduce survival and 
lower QOL of cancer patients and hence it is necessary to study these and manage such 
conditions effectively.9  
Private Insurance
44%
Medicare
33%
Out of Pocketa
4%
Medicaid
4%
Other*
15%
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Depression as a comorbidity: 
Diabetes, COPD/asthma and psychosocial stress are some of the commonly associated 
comorbidities with cancer that further lead to a reduced QOL.8 The prevalence rates of 
psychosocial stress in cancer patients ranged from around 23% to 53%.8 Untreated psychiatric 
comorbidities in patients with cancer have a significant impact on disability, quality of life and 
they tend to worsen if not treated adequately.10 Depression is one of the most commonly 
associated comorbid psychiatric condition with any type of cancer. As compared to anxiety and 
adjustment disorder, the prevalence of depression is 12% higher amongst cancer patients.11 In 
addition, as compared to those without cancer, the prevalence of depression is higher in cancer 
survivors.12 Clinicians working in cancer services have recognized that depression is often 
undiagnosed and untreated and that these shortcomings in care can have substantial effects, not 
only on patients' quality of life but also on their acceptance of cancer treatments.13 There is 
evidence to support that pharmacological treatment mainly tricyclic antidepressants and 
psychotherapy used to treat depression improve palliative care in cancer patients.14  There is also 
evidence to support that the completion rate of cancer treatment is higher when the patient is 
receiving some treatment for comorbid depression.15 Managing depression thus along with 
improving QOL of patients also improves cancer treatment outcomes. Studies have 
demonstrated that comorbid depression is also associated with an increase in total healthcare 
expenditure by $6301 as compared to cancer patients without depression.16 On comparing 
expenditures of cancer patients with depression and those without depression, the highest cost 
difference was found in prescription drugs ($2,297 higher for those with depression) and other 
expenses that included office-based and outpatient visits ($715 higher for those with 
depression).16 The overall use of psychotropic drugs in palliative care of cancer has increased 
from 2002 to 2009.17 Depression could be treated by either pharmacotherapy using different 
types of antidepressants or by psychotherapy using methods such as counselling sessions, 
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certain social media interventions, etc. Studies have suggested that patients report higher interest 
in counseling as compared to antidepressants however, the prevalence of antidepressants is still 
higher than support groups or counseling for managing depression. 18,19  Since, the mechanism 
of action and the side effects of these antidepressant classes differ from each other, it would be 
hypothesized in our study that they would have varied effect on certain patient outcomes such 
as quality of life. 
Antidepressants: 
There are various classes of antidepressants such as tricyclic antidepressants (TCAs), 
selective serotonin reuptake inhibitors (SSRIs), serotonin- norepinephrine reuptake inhibitors 
(SNRIs), monoamine oxidase inhibitors (MAOIs) and atypical antidepressants (miscellaneous 
agents). Depression is a result of decreased levels of neurotransmitters like norepinephrine and 
serotonin in the synapse. All the above-mentioned antidepressants act by increasing the amount 
of such neurotransmitters. The mechanism of action of all these different classes of 
antidepressants differ from each other. TCAs, SSRIs and SNRIs are reuptake inhibitors and they 
block the reuptake of neurotransmitters, which increases their amount in the synapse. TCAs and 
SNRIs increase serotonin and norepinephrine both whereas SSRIs only increase serotonin. 
MAOIs act by decreasing the degradation of neurotransmitters in the synapse thus increasing 
their amount. Monoamine oxidase is the enzyme responsible for breaking down the 
neurotransmitters, which is blocked by the MAOIs.20 Miscellaneous agents also act by 
enhancing the level of dopamine, serotonin or norepinephrine in the synapse. Figure 2 depicts 
the different mechanism of actions of different classes. SSRIs are usually the most frequently 
prescribed antidepressants in general population.21 If the trend is similar in cancer population 
with depression is still ambiguous. The side effects that are associated with specific classes of 
antidepressants differ. It has been mentioned in the literature that SSRIs are usually the most 
tolerable.22 Table 1 summarizes the side effects and examples of each antidepressant class.  
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From a financial perspective, MAOIs are the most expensive with around $50-$80 out of pocket 
for 30 tablets followed by SNRIs at $20 - $50, TCAs at $10 - $15 and the cheapest option is 
SSRIs at $6 -$7 for 30 tablets.23 Looking at the prices, it is evident that the financial burden 
arising across these classes would be varied. It is thus necessary to study the patterns of use 
associated with individual classes of antidepressants and psychotherapy and to assess cost and 
QOL outcomes associated with the same to manage depression efficiently. It would be 
hypothesized in our study that the costs of cancer patients would differ significantly based on 
the antidepressant that they have been prescribed. 
 
 
 Desipramine – TCA, Maprotiline, Trazodone – Miscellaneous Agents, Fluoxetine- SSRI 
Figure 2: Summary of mechanism of action of all the antidepressant classes24 
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Table 1: Side effects along with examples of each class of antidepressant 
*Monoamine oxidase inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       
Antidepressant Side effects Examples 
SSRI Nausea, sleep disturbances, sexual dysfunction, appetite 
changes, headache, dry mouth, slightly abnormal heart 
rhythms  
Fluoxetine, Paroxetine, 
Citalopram 
SNRI All of the side effects of SSRIs, hypertension, tachycardia Duloxetine, Venlafaxine 
TCA Dry mouth, dizziness, blurred vision, constipation, sedation, 
orthostatic hypotension, tachycardia  
Amitriptyline, 
Imipramine, Desipramine 
MAOI* All of the side effects of TCA, skin reaction, weight gain Isocarboxazid, 
Phenelzine, Selegiline 
Miscellaneous 
Agents 
Drowsiness, hypercholesterolemia, weight gain Bupropion, Vilazodone, 
Trazodone, Maprotiline 
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CHAPTER II: LITERATURE REVIEW 
 
Section 2.1: Literature review 
 
A literature review was conducted in order to assess the effects of antidepressants on 
improving the quality of life of cancer patients and assessing the healthcare utilization 
associated with it. The review was conducted using certain specific search terms. Based on the 
literature and the background knowledge, we hypothesized that the effects of antidepressants on 
QOL and the healthcare utilization associated with them would differ based on the different 
classes of antidepressants and the results/findings would then help the patients and providers 
manage depression more effectively. 
Section 2.2: Systematic literature review on the effects of antidepressants on improving 
the QOL of cancer patients and healthcare utilization associated with the same 
 
A literature review was conducted in March 2017 using PubMed/Medline, CINAHL and 
Google Scholar. The search term used was a combination of : (((("Antidepressive 
Agents/economics" [Mesh] OR "Antidepressive Agents/organization and administration" 
[Mesh] OR "Antidepressive Agents/therapeutic use" [Mesh])) AND ("Depression/drug therapy" 
[Mesh] OR "Depression/economics" [Mesh] OR "Depression/epidemiology" [Mesh] OR 
"Depression/prevention and control" [Mesh] OR "Depression/therapy" [Mesh])) AND 
"Neoplasms" [Major]) AND Humans [Mesh] AND English [lang] AND cancer [sb] AND adult 
[MeSH]. Titles and abstracts were screened. The following inclusion/exclusion criteria were 
utilized: 
Inclusion Criteria: 
➢ Studies including outcomes related specifically to antidepressants. 
➢ Studies published in English. 
➢ Studies conducted on adult population over 18 years of age. 
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Exclusion Criteria: 
➢ Not including any health outcomes. 
➢ Not looking at depression as a comorbidity. 
➢ Studies evaluating depression outcomes of the caregiver/spouse. 
➢ Only psychosocial interventions. 
The search criteria gave 372 articles. After removing duplicates, there were around 235 articles. 
Applying the filters as per mentioned in the inclusion/exclusion criteria resulted into 71 articles. 
These 71 articles were then screened by reading the titles and abstracts, out of which, 9 were 
included in the final literature review.15,18,19, 25-30 These were most relevant to the study and 
focused mainly on patient reported outcomes as opposed to just clinical outcomes. Figure 3 
below depicts a flowchart of the article selection process. 
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Figure 3: Article Selection Process 
 
 
 
Total results through databases searching (n= 372) 
 
Titles and abstracts reviewed for eligibility (n=71)  
 
Articles screened for eligibility for studies published in 
English and conducted on adult population (n=235) 
 
Studies included (n= 9) 
 
Remove duplicates (n=137) 
 
Articles excluded (n=62): 
• Antidepressants not the 
primary focus (n=34) 
• Narrative review/case reports 
(n=15) 
• Not the required outcomes 
(n=5) 
• Depression not a comorbidity 
or depression of the 
caregiver/spouse (n=5) 
• Pediatric population (n=2) 
• Only psychosocial 
intervention (n=1) 
 
Article excluded (n=164) 
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A study was found looking at patterns of use and predictors of antidepressants,18 another 
was found looking at the healthcare expenditures25 whereas all others were looking at 
QOL.15,19,26-30 Most of the studies were clinical trials conducted on a small sample size and were 
restricted to either one type of cancer or just one particular antidepressant intervention. 
Therefore, our study would help in filling these gaps in the literature by looking at all types of 
cancers and comparing all the classes of antidepressants in a nationally representative sample 
thus increasing the generalizability. 
Section 2.3: Literature summary 
 
Most of the articles out of the 71, focused mainly on the clinical effects such as level of 
neurotransmitters in the brain or other pathology resulting from the antidepressants rather than 
focusing on the patient reported outcomes. In addition, many studies reported only the 
prescribing trends of antidepressants in the population without cancer or did not focus on QOL 
or healthcare utilization.  
The nine studies that were selected were mainly those that reported QOL of cancer 
patients or the depression scores for the same.15,19,26-30 These were mainly clinical trials looking 
at the effects of one of the antidepressants on depression of cancer patients mainly including 
specific types of cancers.15,26-28 Table 2 would summarize the studies finalized for the literature 
review. 
Patterns and predictors of antidepressant use: 
 A study conducted by Fisch et al. prospectively looked at patterns of use and predictors 
of antidepressant use in ambulatory cancer patients with common solid tumors.18 It was 
observed that, antidepressants were prescribed in 19% of all patients. The predictors identified 
with the use of antidepressants were depressive symptoms, family history of depression, 
concurrent medication use, cancer treatment status and certain other clinical and demographic 
11 
 
variables. However, the authors did not look at classes of antidepressants separately. In addition, 
the study sample was restricted to ambulatory breast, prostate, colon/rectum or lung cancer 
patients. 
Healthcare Expenditures: 
 A study conducted by Alwhaibi et al. examined the association between depression 
treatment and healthcare expenditures among elderly with depression and incident cancer using 
Surveillance, Epidemiology and End Results (SEER) – Medicare.25 They suggested that, the 
average 1-year total healthcare expenditures after depression diagnosis were $38,219 for those 
not receiving any depression treatment, $42,090 for those receiving antidepressants, $46,913 
for those who received psychotherapy only and $51,008 for those receiving both the therapies  
(antidepressant and psychotherapy). Thus, the costs associated were the highest for those 
receiving both the therapies followed by psychotherapy only. This study however looked only 
at elderly population and restricted only to incident breast, colorectal or prostate cancer. In 
addition, the authors did not look at classes of antidepressants separately. 
Quality of Life (QOL): 
There were studies conducted by Navari et al.,15 Fisch et al.,26 Holland et al.,27 and 
Roscoe et al.28 which looked at effects of any one of the antidepressant namely paroxetine, 
fluoxetine or desipramine on depression amongst cancer patients. The studies mentioned above 
were prospective clinical trials focusing on one particular antidepressant rather than comparing 
outcomes across different classes of antidepressants. A study conducted by Navari et al. looked 
at the effects of fluoxetine on treating depressive symptoms in patients with early stage breast 
cancer undergoing adjuvant therapy. It was found that 87% of the patients treated with 
fluoxetine had a significantly higher completion rate of the adjuvant treatment as compared to 
50% in the placebo group. The number of patients with a significant improvement in the QOL 
12 
 
was higher in the fluoxetine group as compared to those in the placebo group (79.6% vs 22.2%). 
The subgroup of patients showing higher levels of depressive symptoms on the two-question 
screening survey were the most likely to benefit from the treatment.15 In a study conducted by 
Fisch et al., the effects of fluoxetine on QOL were studied. It was observed that, patients treated 
with fluoxetine exhibited a significantly greater improvement in QOL as shown by the 
Functional Assessment of Cancer Therapy–General (FACT-G) scores (improved by 8.82 points 
from baseline to the fifth visit), compared with patients given placebo (improved by 5.64 points 
from baseline to the fifth visit). The level of depressive symptoms expressed was lower in 
patients treated with fluoxetine.26 It was observed that, when fluoxetine was compared to 
desipramine by Holland et al., both were effective in treating depressive symptoms, with 
fluoxetine being slightly better than desipramine in terms of efficacy and improving QOL (mean 
change for Short Form Health Survey scores was higher with fluoxetine).27 Roscoe et al. studied 
the effects of paroxetine on reducing depression amongst cancer patients. It was found that 
paroxetine had an effect on decreasing depression, as observed from the reduced CES-D scores 
(reduced from 14.7 to 8.8 across four cycles) and POMS-DD scores (reduced from 2.9 to 1.2 
across four cycles) as compared to placebo group (CES-D scores reduced from 14.7 to only 12.6 
and POMS-DD scores reduced from 3.2 to only 2.2 across four cycles). The decrease in 
depression over time was significant for both the measures namely, CES-D and POMS-DD, 
which indicate a positive effect of the antidepressant.28  
A study conducted by Lloyd-Williams et al., looked at the longitudinal effect of 
antidepressant medication in a cohort of advanced cancer patients. It was a prospective study, 
where recruited patients were asked to fill baseline and follow-up questionnaires for assessment. 
The questionnaires used were PHQ 9 (Patient Health Questionnaire) and EDS (Edinburgh 
depression scale) tools for measuring depression. It was observed that 25% of patients were 
taking some antidepressant medication at some point during the trial period. 77% patients were 
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prescribed SSRIs and none were prescribed TCAs. Patients taking some antidepressant reported 
a significantly lower score on both EDS (3.18 point score reduction) and PHQ 9 (2.71 point 
score reduction) as compared to those taking none indicating a lesser tendency towards 
depression and hence a positive effect of the medication.29 However, in this case, the 
antidepressants were not compared to psychotherapy. 
There was another study conducted by Vyas et al., which was a population-level analysis 
looking at the impact of depression treatment on health-related QOL among adults with cancer 
and depression using Medical Expenditure Panel Survey (MEPS). It was observed that, adults 
who reported psychotherapy with or without any antidepressant had higher Physical Component 
Score (PCS) indicating a positive effect of the treatment (mean = 40.97), as compared to those 
without any treatment (mean = 40.72) or with antidepressants only (mean = 39.87), this 
difference was however not significant. Mental Component Scores (MCS) was the lowest for 
those receiving psychotherapy with or without any antidepressant (mean = 39.23) as compared 
to those without any treatment (mean = 43.78) or those with antidepressants only (mean = 
44.37), this difference was significant. The study thus, suggested that QOL as measured by PCS 
was numerically the highest for psychotherapy whereas that measured by MCS was the highest 
for antidepressants only. However, this study did not look at classes of antidepressants 
separately.30 
Based on a study conducted by Wu et al., which was a survey-based prospective study, 
51.4% women were extremely interested in individual counseling, 38.1% women were 
interested in support group whereas antidepressant medications were rated the lowest. Interest 
for each of the treatments was not related to demographic/disease factors. It was positively 
related to self-rated health. Women with higher self-rated health reported more interest in 
counseling than those with lower self-rated health.19 
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Table 2: Literature Summary 
 
Study Objective Study Design Sample Conclusion 
Patterns of use/ Predictors 
Fisch et al.18 To identify 
determinants of 
prescribing 
antidepressants 
Prospective 
observational 
study 
Ambulatory 
patients with 
breast, prostate, 
colon/rectum or 
lung cancer 
-   Antidepressants -19% 
Individual counseling - 
8.6%  
Support group -8% 
-   Predictors: 
Depressive symptoms, 
family history of 
depression, concurrent 
medication use, cancer 
treatment status, poor 
quality of life and 
demographic variables 
Healthcare expenditures 
Alwhaibi et al.25 
 
 
 
 
To examine the 
association 
between depression 
treatment and 
healthcare 
expenditures  
Retrospective 
longitudinal 
study using 
SEER* dataset 
Elderly 
Medicare 
beneficiaries 
with incident 
breast, colorectal 
or prostate 
cancer 
-   The use of 
combination of 
antidepressant and 
psychotherapy was 
associated with the 
highest total 
expenditures followed 
by psychotherapy only. 
 
Quality of Life (QOL) 
Navari et al.15 Fluoxetine v/s 
Placebo in breast 
cancer patients 
Randomized 
prospective trial 
Newly 
diagnosed early 
stage breast 
cancer patients 
- Higher QOL and 
completion rate of 
cancer treatment with 
the fluoxetine group 
 
Fisch et al.26 To determine 
whether fluoxetine 
improves overall 
quality of life 
(QOL) in advanced 
cancer patients 
with symptoms of 
depression revealed 
by a simple survey. 
 
Prospective 
double blinded 
trial to receive 
either fluoxetine 
or placebo for 12 
weeks 
Advanced 
cancer patients 
with an expected 
survival between 
3 and 24 months  
-   Fluoxetine exhibited 
a higher significant 
improvement in QOL as 
compared to the placebo 
group and decreased 
depressive symptoms, as 
indicated by the FACT-
G scores 
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Holland et al.27 Fluoxetine v/s 
desipramine in 
depressed women 
with advanced 
cancer 
Prospective 
double-blinded 
trial 
Women with 
advanced cancer 
- Both effective, with 
fluoxetine being slightly 
better than desipramine 
in terms of improving 
efficacy and QOL 
Roscoe et al.28 Paroxetine v/s 
Placebo in breast 
cancer patients 
Prospective 
double-blinded 
trial 
Female breast 
cancer patients 
receiving at least 
four cycles of 
chemotherapy 
 
- Reduced depression 
with paroxetine as 
observed from the CES-
D and POMS-DD scores  
Lloyd-Williams 
et al.29 
 
 
 
 
 
To observe the 
longitudinal effect 
of antidepressant 
medications in a 
cohort of advanced 
cancer patients 
Longitudinal 
observational 
prospective study 
Patients with 
advanced cancer 
- Patients taking some 
antidepressant reported 
a lower EDS and PHQ 
score compared to those 
taking none indicating a 
lesser tendency towards 
depression 
 
Vyas et al.30 
 
 
 
 
 
To examine the 
association 
between depression 
treatment and 
HrQOL among US 
adults with cancer 
and depression 
 
Retrospective 
study using 
Medical 
Expenditure 
Panel Survey 
Cancer patients 
above 18 years 
of age 
- PCS was the highest 
for psychotherapy 
whereas MCS was the 
highest for 
antidepressants  
Wu et al.19 To investigate 
treatment 
preferences for 
depression 
Prospective 
observational 
study 
Women with 
breast cancer 
arriving for a 
surgical follow-
up, 
chemotherapy or 
radiation therapy 
appointment 
 
-  45.2% reported higher 
levels of  interest in 
counseling compared to 
antidepressants 
-  Women with higher 
self-rated health    
reported more interest in 
counseling 
 
* Surveillance, Epidemiology and End Results 
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Section 2.4: Gaps in literature 
 
It is evident from the existing literature that antidepressants help in improving QOL and 
outcomes, such as completion rate of the cancer treatment. However, none of the studies have 
looked and compared all the different classes of antidepressants. Most of the studies have either 
looked at just one of the antidepressant or just looked at one type of cancer. Moreover, most of 
the studies conducted have been randomized controlled trials with a small sample size, which 
limits generalizability of the study. It is thus unclear from the existing literature as to which 
class of antidepressant would prove to have maximum benefits in improving QOL. In addition, 
none of the studies have looked at healthcare utilization/ healthcare costs associated with the 
classes of antidepressants and the sociodemographic factors associated with each. The study 
conducted by Alwhaibi et al.25 looked at healthcare utilization associated with antidepressants 
as a whole and did not look separately at individual classes. In addition, the authors did not look 
specifically at prescription medicine costs or office-based visit costs, which would be more 
specific to the depression therapy classes. Our study would thus help in addressing these 
limitations of the existing literature. 
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Section 2.5:  Specific Aims 
 
Aim 1: To determine the patterns of use of antidepressants amongst cancer patients in the 
US with comorbid depression and characterize the utilization of antidepressants based on 
sociodemographic characteristics 
A: To determine the patterns of use and prescription trends across different classes of 
antidepressants 
B: To characterize the sociodemographic factors associated with the utilization of 
antidepressants 
Aim 2: To compare costs and healthcare utilization (office-based visits) of cancer patients 
across different classes of antidepressants in the US 
A: To compare the prescription medicines expenditures, overall costs and out of pocket 
expenses of cancer patients with comorbid depression across different classes of 
antidepressants 
B: To compare office-based visits along with the expenses related to these across cancer 
patients with comorbid depression classified based on the class of antidepressants 
Aim 3: To compare quality of life (QOL) of cancer patients in the US with comorbid 
depression across different classes of antidepressants and psychotherapy 
A: To compare the physical and mental component score (PCS/MCS) across different 
classes in order to assess quality of life of cancer patients with comorbid depression 
B: To compare Patient Health Questionnaire – 2 (PHQ-2) scores and the frequency of 
depression obtained from Short Form version 12 (SF-12) to assess quality of life of 
cancer patients along with comorbid depression 
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Section 2.6: Conceptual Framework 
 Conceptual framework for this research was based on the Andersen Behavioral Model. 
The model parameters were guided by existing literature and studies conducted in the same area. 
The model was as follows: 
 
                 
 
 
 
                                                              
                 
 
Certain predisposing and outcome variables for our study were identified based on 
studies conducted by Fisch et al. and Wu et al., which looked at patterns of use and predictors 
for the use of certain drugs.18,31 Outcome variables for specific aim 2 along with certain enabling 
and need factors were identified based on past studies looking at the costs associated with a 
particular class of medication or economic burden studies.31,32 The outcome variables for 
specific aim 3 were identified using the past QOL studies that have been summarized.15,19,26-30 
There has also been a study conducted by Üstündağ et al. looking at factors affecting QOL of 
patients on chemotherapy which also provided the framework for selecting certain predisposing 
and QOL outcome variables.3 
 
Outcomes: 
1. Patterns of use of antidepressants (specific aim 1) 
2. Prescription and office-based visit costs associated 
across classes of antidepressants (specific aim 2) 
3. QOL across classes of antidepressants (specific 
aim 3) 
Need Factors: 
Overall health status, 
cancer characteristics 
(cancer type, remission 
stage, number and type 
of comorbidities) 
Enabling Factors: 
Employment status, 
income 
Predisposing Factors: 
Demographics (Age, 
Gender, Marital 
Status) and Social 
Structure (Education, 
Race) 
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Section 2.7: Rationale 
 
As stated above, depression has been proven to worsen the condition of cancer patients 
and managing the same has shown positive effects not only on the QOL but also on the outcomes 
associated with cancer treatment.15,19,26-28 Despite that, there have not been many studies 
assessing and comparing the effects of different classes of antidepressants on patient outcomes. 
In addition, many of these studies have restricted to one single type of cancer and none of them 
have looked at the comparison of healthcare costs or healthcare utilization across classes of 
antidepressants.15,19,26,28 There have been cost studies comparing the psychosocial approaches 
(self-administered psycho-educational intervention, nursing, tele and home care more costly and 
effective than the usual care with no such intervention) used in treating depression in cancer 
population; however, those did not take into account the pharmacotherapies available.33,34  There 
have been no studies comparing various classes of antidepressants used in the management of 
depression and comparing these with psychotherapy. Studies have only suggested that the effect 
on reducing depression is higher when pharmacotherapy is used along with psychosocial 
interventions and it has been assumed that pharmacotherapy would have greater effect than 
psychosocial interventions.35 These have however been narrative reviews and no formal study 
has been conducted yet comparing classes of antidepressants along with psychotherapy. This 
study would thus help in providing evidence for the association between antidepressants and 
QOL along with the costs associated across classes of antidepressants/ psychotherapy. 
Furthermore, most of the studies conducted were either meta-analysis/narrative 
reviews36,37 or randomized controlled trials (RCTs)15,26,27,28 which limit generalizability of the 
study. Hence, there is a need to conduct a population-based study, which would look at effects 
of different interventions and compare those, and which would help the patients and the 
healthcare providers manage depression better. This study would thus be a nationally 
representative population-based study using Medical Expenditure Panel Survey (MEPS) 
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looking at different classes of antidepressants along with psychotherapy and analyzing which 
of the intervention is the most effective in improving the quality of life (QOL) and the healthcare 
utilization/costs associated with each. Sociodemographic characteristics and the general 
patterns of use of antidepressants would also be studied. Such study is important for 
understanding the subgroup differences in depression treatment patterns, in order to promote a 
more effective management of depression amongst cancer patients. In addition, studying costs 
and quality of life associated with each class of antidepressant would help in understanding the 
economic burden on cancer patients and the value associated with each. Existing literature 
suggests that the economic burden on cancer patients other than the costs incurred from the 
cancer treatment are mainly because of office-based visit costs and prescription medicine 
costs.16,32 These costs and QOL outcomes along with patterns of use would be explored in our 
study across the classes of antidepressants and psychotherapy. 
Based on the already existing literature, this would be the first population-based study 
that would compare the different classes of antidepressants along with just psychotherapy and 
would also include all types of cancer and not restrict to just one. This study would provide 
certain guidelines to the provider, encouraging/ discouraging prescription of any particular class 
of antidepressant or psychotherapy and providing evidence to make certain decisions so as to 
choose the depression therapy effectively. QOL outcomes would help clinicians in making a 
better-informed decision regarding prescription of any therapy. In addition, it would also help 
policy makers in guiding their decision for coverage of any particular antidepressant or 
encouraging coverage of specific psychotherapies in a specific population.  
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CHAPTER III: SPECIFIC AIM I 
 
Aim 1: To determine the patterns of use of antidepressants amongst cancer patients in the 
US with comorbid depression and characterize the utilization of antidepressants based on 
sociodemographic characteristics 
A: To determine the patterns of use and prescription trends across different classes of 
antidepressants 
B: To characterize the sociodemographic factors associated with the utilization of 
antidepressants 
Section 3.1: Methods 
Design:  
A cross-sectional, retrospective study design was implemented for all the specific aims  
Data: 
A nationally representative publicly available dataset called Medical Expenditure Panel 
Survey (MEPS) was used for the study. MEPS, which began in 1996, is a set of large-scale 
surveys of families and individuals, their medical providers (doctors, hospitals, pharmacies, 
etc.), and employers across the United States conducted by the Agency for Healthcare Research 
and Quality (AHRQ). The MEPS household component files provide data on demographics of 
the participants, population characteristics, medical conditions, prescribed medicines, data on 
inpatient and outpatient/office-based visits and all the expenses made by the patient including 
out of pocket and any type of insurance coverage offered. The full year consolidated file of the 
household component also contains information on the quality of life and the physical/mental 
wellbeing of the patient, which was used for the study. Data from January 2005 to December 
2015 data files was used for this study. Full year consolidated files were used to identify patient 
demographics, medical conditions files were used to identify patients, prescription medicines 
22 
 
files were used to identify the use of antidepressants, and office-based medical provider visits 
files were used to identify psychotherapy visits for depression. 
Study sample: 
The medical conditions file of the household component provides the International 
Classification of Diseases (ICD-9) codes for patient diagnoses. These codes were used to 
identify patients. Clinical Classification Software (CCS) collapses categories based on ICD-9 
codes and generate more meaningful codes which can be used to look at broader categories like 
‘cancer’ and not a specific type of cancer. Hence, clinical classification codes of 11-44 were 
used to identify cancer patients.38 There were around 204,732 people who responded to MEPS 
from 2005 to 2015. The study sample was then restricted to adult respondents who were 
diagnosed with or had cancer after the age of 18 years (n = 60,237), as identified by the CCS. 
Adults who died during the process of reporting were excluded and hence the study sample 
consisted of cancer survivors. The sample was then restricted to 21,413 patients who also had 
an ICD code of 296 or 311 or a clinical classification code of 657, indicating depression 
condition. These 21,413 patients thus had cancer along with depression. Patients who also had 
an ICD code for bipolar disorder or schizophrenia (n = 3,742) were further excluded, since, in 
these cases antidepressants are used for non-depression conditions. The final study sample, thus 
include 17,671 cancer patients along with comorbid depression, diagnosed after the age of 18 
years in the US. Figure 4 depicts the final sample size.    
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     *These were the cases identified in the US with cancer and depression diagnoses and     
   formed the final sample size      
Figure 4: Sample size flow chart for all the study aims  
Variables: 
Therapeutic drug class variables: 
Prescription Medicines files from 2005-2015 were used to identify the antidepressants, 
if any, prescribed to a patient. MEPS classifies drugs based on their therapeutic class under 
‘Multum Therapeutic Class’. A specific code is given to one class of drugs under these Multum 
classes. These codes were used to capture the drug use. Following Table 3 summarizes the codes 
used. 
 
MEPS 2005-2015 Population 
(N= 204,732) 
Cancer patients ≥ 18 years of age 
(N=60,237) 
Cancer patients ONLY with 
comorbid depression (N=17,671)* 
Cancer patients with comorbid 
depression (N=21,413) 
Excluded those with bipolar 
disorder and schizophrenia 
(N=3,742) 
24 
 
Table 3: Codes used to identify antidepressant classes using MEPS Prescription Files 
 
Multum class Code Antidepressant class 
TC1S1 208 SSRI 
TC1S1 209 TCA 
TC1S1 308 SNRI 
TC2S1 250 MAOI 
TC2S1 76 Miscellaneous* 
TC1S1 307, 306 Miscellaneous (including 
Tetracyclic, Phenyl 
piperazine)** 
* Separately coded as miscellaneous antidepressant agents by MEPS  
** Considered these categories as miscellaneous for this study’s purposes 
 
Based on the codes mentioned above, a new categorical variable was created indicating 
the classes of antidepressants (one specific or in combination) that were prescribed to a patient. 
This variable also had two more categories. One was for identifying patients who did not have 
any antidepressant prescribed but had psychotherapy or counseling session in order to manage 
depression and another identifying those who used antidepressants and psychotherapy both 
prescribed. Psychotherapy or counseling sessions were identified using office-based medical 
provider visits files. These files capture psychotherapy by asking questions like: ‘Type of 
Medical person the patient talked to on the visit’ (10 = Psychologist) and ‘Best category for care 
the patient received on visit’ (4 = Psychotherapy/Mental Health Counseling). In addition, 
modified CCS code of 657 captured under office-based procedural codes was also used to 
identify these visits. The final categorical variable for the treatment of depression thus had six 
categories, namely: SSRI, TCA, SNRI, Miscellaneous (tetracyclic and phenyl piperazine agents, 
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other unclassified antidepressants), Psychotherapy only and both (Antidepressant and 
Psychotherapy). MAOIs were removed from the classification since, they were not prescribed 
anymore for depression amongst cancer patients and the sample size in that particular class was 
found to be null. The combinations of antidepressants prescribed were identified using the round 
number and the panel number that the medicine was obtained in, each unique round consisting 
of approximately 3 months. The patients were considered to be using combinations of 
antidepressants, if they had the same round number for any two classes of antidepressants. The 
names of antidepressants under each class included by MEPS are summarized in Appendix 
Table 1. 
Prescription drug characteristics and patterns of use variables: 
Prescription medicines files were used to obtain drug characteristics. Variables such as 
the quantity of prescribed medicines and days supplied of prescribed medicine were used as 
prescription drug characteristics. Antidepressants were considered to be given in combinations 
if the round number that the patient reported for these was the same. It is possible that within 3 
months of a specific round a patient was switched to another class, this would however be 
captured as a combination in our study. Combinations of antidepressants with psychotherapy 
were identified too. The trends in the use of different classes of antidepressants from 2005-2015 
was identified using the drug codes specific to a particular year, which was obtained from the 
Panel Round number captured in the full year consolidated files. The patterns of use were further 
described using sociodemographic variables. 
Cancer characteristics and comorbidities: 
 Type of cancer was identified using full year consolidated files. Cervical, breast, colon 
and lung were the major types of cancer identified and prostate, melanoma, liver, kidney and 
pancreatic cancer were clubbed under one “other/non-specified” category along with some non-
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specified cancers. Arthritis, asthma, diabetes and high blood pressure were identified as major 
comorbidities associated with cancer patients along with depression based on the past 
literature.8,30,39 The number of comorbidities (combinations of those mentioned above) were 
identified across classes of antidepressants/psychotherapy.  
Sociodemographic variables: 
Full Year Consolidated files were used to obtain sociodemographic characteristics of 
patients and compare them across different classes of antidepressants. The variables included 
were sex, race, age, marital status, income, education and employment status. Sex, race and 
marital status were used directly from MEPS whereas age, income, education and employment 
status were recoded into meaningful categories. Age was a continuous variable and it was 
recoded into 3 categories: “18-44 years”, “45-65 years” and “>65 years”. Income was also a 
continuous variable which was collapsed into 3 categories: “low” (< $12,060), “middle class” 
($12,060 - $48,240) and “high” (> $48,240). These income ranges for these categories were 
identified based on the federal poverty line (FPL). The FPL for 2018 was $12,060 annual 
income which was considered 100%, hence below this limit was identified as low income, 
between 100-400% ($12,060 - $48,240) of FPL was identified as middle class income and over 
400% FPL (>$48,240) was identified as high income. These ranges were identified based on 
another study looking at drug expenses and the FPL guidelines.31,40 Education was recoded to 5 
categories: “0: No education” (Kindergarten only and no years of schooling), “1: Elementary 
(Elem)/ Middle (Mid) School” – grades 1-8, “2: High school” (grades 9-12), “3: ≤ 4 years of 
college” (≤ 4 years of college after the 12th grade) and “4: 5+ Years College”. Employment was 
recoded to form two broader categories, namely: “Employed” and “Unemployed”.  
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Statistical Analyses: 
Patterns of use of antidepressants and the combinations used were assessed using 
number of prescriptions that were obtained from the Prescription Medicines Files using the drug 
codes. Event-level files were summarized to patient-level files using PROC MEANS and PROC 
TRANSPOSE procedures in SAS. ANOVA procedure was used to compare means of quantity 
and days across different classes of antidepressants. Chi square tests were used to compare and 
assess the significance of sociodemographic characteristics across different classes of 
antidepressants and based on these results, characteristics were included in a multinomial 
logistic model predicting the likelihood of receiving any particular class of antidepressant. The 
preliminary chi square tests (PROC SURVEYFREQ) were significant for all the 
sociodemographic factors such as sex, age, income, race, marital status, employment status and 
education, hence, all of these were included in the regression model. Multinomial logistic 
regression approach (PROC SURVEYLOGISTIC) was then used to calculate odds ratios (OR) 
and estimate the likelihood of receiving any particular antidepressant and hence define the 
patterns of use and predictors of receiving the treatment further. The model used for multinomial 
logistic regression was as follows: 
Logit (y=a*) = log    p(y=a*)     = β0 + β1 . Age + β2 . Gender +  β3 . Race+ β4 . Marital Status +                         
                                1-p(y=a*)       β5 . Education + β6 . Employment Status + β7 . Income + Ɛa 
 
*-Either SSRI, Miscellaneous agents, SNRI, TCA, Psychotherapy (Reference = No 
antidepressant/psychotherapy), a-Error Term 
 
Trends in the utilization of antidepressants across the study period of 2005 to 2015 were 
compared by plotting graphs for each class of antidepressant/ psychotherapy. For trends, the 
percentages, calculated using the following formula, were plotted for each year:  
           Number of those who were prescribed xa in one particular year                  
Total number of antidepressant/psychotherapy prescription in that particular year 
a – SSRI/Miscellaneous Agents/SNRI/TCA/Psychotherapy 
100 
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Trends throughout the study period were compared for each individual class by 
conducting Cochran-Armitage trend test for categorical data. After running the analyses, the 
data was summarized using means and frequencies for continuous and categorical variables 
respectively and OR for logistic regression results. All the analyses was weighted by using 
pooled weights from all the years. All the analyses were conducted using 0.05 as the significance 
level. The hypothesis tested in this analysis was that the patterns of use and the trends of 
antidepressants would differ significantly across the groups. In addition, the sociodemographic 
characteristics would also differ and would be significantly associated with the likelihood of 
receiving any specific class of antidepressant/ psychotherapy. SAS v9.4 and MS Excel 2016 
were used for the analyses and for plotting graphs. 
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Section 3.2: Results 
Aim 1A:  To determine the  patterns of use and prescription trends across different classes 
of antidepressants 
Total sample size for the study consisted of 17,671 (weighted frequency = 16,478,908) 
cancer patients with depression. Out of this, 32.08% (n = 5,669) had some antidepressant 
prescribed to them either in combination or of one particular class. 15.30% (n = 2,705) reported 
psychotherapy or mental counseling for managing their depression. There were around 7.25% 
patients (n = 1,282) who reported the use of both that is pharmacotherapy (antidepressant) and 
psychotherapy both at a time. There were around 53.64% patients (n = 9480) with no treatment 
for depression and hence were untreated. Hence, patients either had untreated depression or 
were prescribed an antidepressant, psychotherapy or a combination of both for managing their 
depression. Amongst those who were prescribed antidepressants, 62.44% patients (n = 3,540) 
were on SSRI, whereas 20.19% (n = 1145) were on miscellaneous agents that also included 
1.09% tetracyclic (n = 62) and 3.2% phenyl piperazine (n = 187) agents in addition to those 
defined as miscellaneous by MEPS, around 13.31% (n = 755) were on SNRI.  4.03% (n= 229) 
patients were on TCA. The sample sizes of patients per antidepressant class along with their 
weighted frequencies are summarized in Table 4.  
Table 4: Sample sizes (unweighted and weighted) per antidepressant class 
 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin-
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants 
 
Antidepressant Frequency Weighted 
Frequency 
Unweighted 
Percent 
SSRI 3,540 3,545,671 62.44 
Miscellaneous Agents 1,145 1,182,517 20.19 
SNRI 755 803,590 13.31 
TCA 229 199,423 4.03 
Total 5,669 5,531,052 100 
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Amongst those who were prescribed antidepressants, around 5.6% patients (n=318) 
reported using combinations of different classes. Out of these 318 patients who were using 
combination therapy, most of them (56.28%, n = 179) were prescribed a combination of SSRI 
and one of the miscellaneous agents (usually Bupropion). Some other combinations identified 
were, SSRI - TCA, SSRI - SNRI and SNRI – miscellaneous agent. There were very few who 
were prescribed some other combinations such as, TCA with either SNRI or a miscellaneous 
agent. SSRI and miscellaneous agents were the most frequently prescribed classes individually 
or in combination. The frequencies of patients receiving a combination therapy are summarized 
in Table 5 along with their weighted frequencies per combination. 
Table 5: Frequencies for combinations of antidepressants 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin-
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants 
MA* - Miscellaneous Agents 
a Other combinations include TCA either with a miscellaneous agent or SNRI 
 
As mentioned above, some antidepressants were also used in combination with 
psychotherapy (n = 1282). SSRI was the most commonly prescribed class along with 
psychotherapy (n = 733, 57.17%). TCA (n = 29, 2.26%) was a rarely prescribed class in 
combination with psychotherapy. These combinations are summarized in Table 6 using 
weighted and unweighted frequencies.  
 
 
Combination of 
antidepressants 
Frequency Weighted 
Frequency 
Unweighted 
Percent 
SSRI – MA* 179 193,074 56.28 
SNRI – MA* 47 53,902 14.77 
SSRI – SNRI 42 44,889 13.20 
SSRI – TCA 34 27,236 10.69 
Other combinationsa 16 20,432 5.03 
Total 318 343,002 100 
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Table 6: Frequencies for combinations of antidepressants along with psychotherapy 
 
Antidepressant with 
psychotherapy 
 
Frequency Weighted 
Frequency 
Percent 
SSRI 733 802,998 57.17 
Miscellaneous agents 338 392,011 26.36 
SNRI 182 122,321 14.19 
TCA 29 25,242 2.26 
Total 1,282 1,282,751 100 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin-
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants 
 
All the above findings suggest that SSRI and miscellaneous agents were the most 
frequently prescribed antidepressants to manage depression amongst cancer patients. These 
were also the classes of antidepressants used most frequently in combination with one another 
or with psychotherapy. 
 Cancer characteristics including the type of cancer, the remission state and other 
comorbidities associated with cancer patients are summarized below in Table 7. Cancer type 
and remission state had more than 90% missing values and hence were excluded from further 
analyses, since they did not have any effect on the outcome variables. Number and type of 
comorbidities had fewer missing values and hence were included in the analyses further. 
Table 7: Cancer Characteristics across classes of antidepressants and psychotherapy 
 
Cancer 
characteristic 
Antidepressants Psychotherapy 
(N=2705) SSRI 
(N=3540) 
MA* 
(N=1145) 
SNRI 
(N=755) 
TCA 
(N=229) 
Cancer Type 
Cervical 
Breast 
Colon 
Lung 
Other/Non-specified 
Missing 
 
37 (1.04) 
46 (1.29) 
11 (0.31) 
6 (0.16) 
64 (1.80)  
3,376 (95.36) 
 
8 (0.69) 
17 (1.48) 
6 (0.52) 
5 (0.43) 
23 (2.00) 
1,086 (94.84) 
 
9 (1.19) 
17 (2.25) 
2 (0.26) 
3 (0.39) 
15 (1.98) 
709 (93.90) 
 
1 (0.43) 
2 (0.87) 
2 (0.87) 
1 (0.43) 
3 (1.31) 
220 (96.09) 
 
19 (0.70) 
31 (1.14) 
9 (0.33) 
1 (0.03) 
33 (1.21) 
2,612 (96.56) 
Remission State 
Yes 
No 
Missing 
 
75 (2.11) 
6 (0.16) 
3459 (97.71) 
 
25 (2.18) 
1 (0.08) 
1,119 (97.72) 
 
23 (3.05) 
0 (0.0) 
732 (96.95) 
 
4 (1.75) 
0 (0.0) 
225 (98.25) 
  
30 (1.10) 
1 (0.03) 
2674 (98.85) 
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Comorbidities 
Diabetes 
Arthritis 
Asthma 
High blood pressure 
Missing 
 
311 (8.78) 
1,029 (29.06) 
413 (11.66) 
1,068 (30.16) 
719 (20.31) 
 
112 (9.78) 
393 (34.32) 
158 (13.79) 
402 (35.10) 
80 (6.98) 
 
88 (11.65) 
290 (38.41) 
96 (12.71) 
272 (36.02) 
9 (1.19) 
 
26 (11.35) 
90 (39.30) 
31 (13.53) 
80 (34.93) 
2 (0.87) 
 
351 (12.97) 
659 (24.36) 
513 (18.96) 
696 (25.73) 
486 (17.96) 
Number of 
comorbidities 
2 
≥3 
Missing 
 
 
2,790 (78.81) 
31 (0.87) 
719 (20.31) 
 
 
1,045 (91.26) 
20 (1.74) 
80 (6.98) 
 
 
734 (97.22) 
12 (1.59) 
9 (1.19) 
 
 
219 (95.19) 
9 (3.94) 
2 (0.87) 
 
 
2,175 (80.41) 
44 (1.63) 
486 (17.96) 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin-
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants 
MA* - Miscellaneous Agents 
 Thus, as seen from the table above, the findings regarding the type of cancer and the 
remission state across classes of antidepressants/ psychotherapy were inconclusive, since 
majority of values were missing. With respect to comorbidities, arthritis and high blood pressure 
were the most commonly associated conditions across all the groups. Almost the entire 
population had at least 2 of these comorbidities. Some even reported having 3 or all of these 
conditions.  
 Quantity of prescribed drugs and days supplied per prescription were then compared 
across different classes to further explore patterns of use. It was found that the quantity of drugs 
prescribed were the highest for miscellaneous agents (mean = 56.57), however the differences 
within classes were not statistically significant (p-value > 0.05 for all comparisons). Days 
supplied of prescribed medicine were the highest for SSRI (mean = 26.27), these were 
significantly higher than that for TCA (p-value = 0.0357), however the other differences were 
not statistically significant (p-value > 0.05). The means for quantity and days supplied of 
prescribed drug are summarized below in Figure 5.  
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Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin-
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants 
MA* – Miscellaneous Agents 
Figure 5: Mean quantity and days supplied of medicine per fill across antidepressant 
classes for cancer patients with depression in the US for the years 2005-2015 
 
Since the differences were not statistically significant, it can be concluded that the 
patterns of use with respect to the quantity and days supplied are similar across different classes 
of antidepressants. 
 In addition, antidepressant and psychotherapy use was tracked across the study period 
to identify the trends. Figure 6 depicts the trends per class. The observed trends remain 
consistent with the findings above where SSRI is the most frequently prescribed class of 
antidepressant followed by miscellaneous agents.  
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Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin-
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants 
MA* – Miscellaneous Agents 
Trends reported are percentages observed per year out of all the antidepressants/ 
psychotherapy prescribed in that particular year 
 
Figure 6: Trends in the use of antidepressants and psychotherapy throughout the study 
period 
 
 As seen from the graph, the use of TCA from 2005-2015 has been minimum and has 
been steady. The use of psychotherapy has increased until 2010 and has been stable ever since. 
In the year 2008, there was a spike increase in the use of SNRI, however, the use decreased in 
2009 and has again increased slightly in 2013 and remained stable ever since. The use of SSRI 
has been more than 50% of all the antidepressants throughout the study period. The year 2009 
witnessed an increase in the use of SSRI over 60%, however it decreased by 2010 and has been 
stable ever since. Out of all of these, a significant change in trend (upward or downward) was 
observed only for SNRI (p-value=0.0385 for a two-sided test), others were all non-significant. 
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Aim 1B: To characterize the sociodemographic factors associated with the utilization of 
antidepressants  
 Sociodemographic characteristics included in our study, age, gender, race, marital status, 
education employment status and income were compared across the classes of antidepressants 
and psychotherapy. The distribution of people per antidepressant/ psychotherapy class by the 
sociodemographic factors mentioned above are summarized in Table 8.  
Table 8: Sociodemographic characteristics of patients receiving antidepressant/psychotherapy 
 
Sociodemographic 
Factor 
Antidepressants Psychotherapy 
(N=2705) SSRI 
(N=3540) 
MA* 
(N=1145) 
SNRI 
(N=755) 
TCA 
(N=229) 
Age, years (range) 
                      Mean 
 
 
48.13 
 
47.54 
 
49.03 
 
50.55 
 
43.23 
Age groups  
             18-44 years 
             45-65 years 
                >65 years 
                  Missing 
 
 
1,381 (39.01) 
1,325 (37.42) 
446 (12.60) 
388 (10.96) 
 
350 (30.57) 
401 (35.02) 
157 (13.71) 
237 (20.70) 
 
247 (32.72) 
333 (44.11) 
78 (10.33) 
97 (12.85) 
 
57 (24.89) 
99 (43.23) 
26 (11.35) 
47 (20.52) 
 
1,333 (49.29) 
897 (33.16) 
128 (4.73) 
346 (12.81) 
Gender 
                       Male  
                   Female 
                  Missing 
 
 
1,063 (30.03) 
2,341 (66.13) 
136 (3.84) 
 
319 (27.86) 
545 (47.60) 
281 (24.54) 
 
186 (24.64) 
487 (64.50) 
82 (10.86) 
 
55 (24.02) 
134 (58.52) 
40 (17.47) 
 
976 (36.08) 
1,633 (60.36) 
96 (3.54) 
Race 
                   Whites 
                   Blacks 
                   Asians 
      Multiple Races 
                  Missing 
  
 
1,943 (54.89) 
668 (18.87) 
534 (15.08) 
300 (8.47) 
95 (2.68) 
 
752 (65.68) 
146 (12.75) 
34 (2.97) 
67 (5.85) 
146 (12.75) 
 
620 (82.12) 
39 (5.17) 
7 (0.93) 
17 (2.25) 
72 (9.54) 
 
85 (37.12) 
114 (49.78) 
3 (1.31) 
3 (1.31) 
24 (10.48) 
 
2,296 (84. 87) 
216 (7.98) 
37 (0.93) 
84 (3.10) 
72 (2.66) 
Marital Status 
 
                  Married 
               Widowed 
               Divorced 
              Separated 
      Never Married 
                 Missing 
 
 
1,478 (41.75) 
254 (7.18) 
552 (15.59) 
126 (3.56) 
871 (24.60) 
259 (7.32) 
 
 
323 (28.21) 
58 (5.07) 
289 (25.24) 
42 (3.67) 
223 (19.48) 
210 (18.34) 
 
 
322 (42.65) 
51 (6.75) 
146 (19.34) 
24 (3.18) 
127 (16.82) 
85 (11.26) 
 
 
79 (34.50) 
20 (8.73) 
34 (14.85) 
4 (1.75) 
48 (20.96) 
44 (19.21) 
 
 
681 (25.17) 
96 (3.54) 
494 (18.26) 
115 (4.25) 
962 (35.56) 
355 (13.19) 
Education 
          No education          
Elem/Mid School 
 
10 (0.28) 
229 (6.47) 
 
14 (1.22) 
156 (13.62) 
 
7 (0.93) 
38 (5.03) 
 
0 (0.00) 
23 (10.04) 
 
108 (4.36) 
477 (17.64) 
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           High School 
   ≤ 4 Years College 
    5+ Years College 
                  Missing 
 
1,037 (29.29) 
872 (24.63) 
204 (5.76) 
1,188 (33.56) 
347 (30.31) 
318 (27.77) 
68 (5.94) 
242 (21.14) 
204 (27.02) 
224 (29.67) 
155 (20.53) 
127 (16.82) 
97 (42.36) 
42 (18.34) 
10 (4.37) 
57 (24.89) 
937 (34.64) 
811 (29.99) 
354 (13.09) 
9 (0.33) 
Employment 
status 
               Employed 
          Unemployed 
                  Missing 
 
 
1,635 (46.19) 
1,534 (43.33) 
371 (10.48) 
 
 
385 (33.62) 
432 (37.73) 
328 (28.65) 
 
 
340 (45.03) 
318 (42.12) 
97 (12.85) 
 
 
68 (29.69) 
112 (48.91) 
49 (21.40) 
 
 
1,147 (42.41) 
1,288 (47.61) 
270 (9.98) 
Income, per year 
                 Mean ($) 
 
 
30,007 
 
31,993 
 
32,513 
 
24,229 
 
24,931 
Income groups a 
                        Low 
           Middle class 
                       High 
                  Missing 
 
610 (17.23) 
2,268 (64.07) 
526 (14.86) 
136 (3.84) 
 
135 (11.79) 
587 (51.27) 
142 (12.40) 
281 (24.54) 
 
80 (10.60) 
468 (61.99) 
125 (16.56) 
82 (10.86) 
 
24 (10.48) 
145 (63.32) 
20 (8.73) 
40 (17.47) 
 
639 (23.62) 
1,654 (61.16) 
316 (11.68) 
96 (3.54) 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin-
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants 
MA* - Miscellaneous Agents 
 a - Low defined as income <100% FPL (<$12,060), middle class defined as income between 
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
 
As seen from the table above, majority of the people in any 
antidepressant/pharmacotherapy group were in the 18-44 years or 45-65 years age group and 
were females. In addition, except TCA (49.78% - Blacks), most of the population in any 
antidepressant/pharmacotherapy group was White. The marital status and education was varied 
across the groups. The distribution between the employed and unemployed groups was uniform. 
Majority of the population belonged to middle class income category across all the groups. In 
bivariate analyses, all these factors were significantly associated with the class of 
antidepressant/psychotherapy at the significance level of 0.05. 
Multinomial logistic regression approach produced the results as stated in Table 9 using 
‘no depression therapy’ as a comparison group for the outcome variable. People who were above 
65 years of age were less likely to receive any antidepressant/ psychotherapy and those between 
18-44 years were more likely to receive psychotherapy as compared to those between the age 
group of 45-65 years. It was observed that, males were less likely to receive SNRI as compared 
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to females. Blacks were less likely to receive SSRI, SNRI or any miscellaneous agent as 
compared to Whites. Asians were less likely to receive SNRI, whereas those who reported 
multiple races including Hispanic were more likely to report the use of psychotherapy as 
compared to Whites. Those who were divorced were more likely to receive any miscellaneous 
agent or psychotherapy, whereas those who never married were more likely to receive 
psychotherapy as compared to those who were married. Those who reported no education, 
elementary/middle school or high school were less likely to receive any treatment for depression 
as compared to those who attended college for ≤4 years. Those who attended college for more 
than 5 years were more likely to receive any miscellaneous agent or psychotherapy as compared 
to those who attended college for ≤4 years. People who were employed were more likely to 
receive SSRI, whereas less likely to receive TCA or psychotherapy as compared to unemployed. 
Income was not significantly associated with the likelihood of receiving any 
antidepressant/psychotherapy. These results are summarized using OR in Table 9. 
Table 9: Multinomial regression results for likelihood of receiving any 
antidepressant/psychotherapy 
 
Sociodemo-
graphic Factor 
Antidepressants (OR, Confidence Intervals)a Psychotherapy 
(OR, Confidence 
Intervals) 
SSRI MA* SNRI TCA 
Age** 
18-44 years 1.145 
(0.966,1.357) 
1.127 
(0.858,1.480) 
1.030 
(0.776,1.368) 
0.802 
(0.420,1.533) 
1.951** 
(1.247,3.052) 
>65 years 0.842 
(0.661,1.073) 
 
0.410** 
(0.260,0.646) 
 
0.504** 
(0.288,0.882) 
0.549 
(0.272,1.107) 
0.154** 
(0.043,0.556) 
45-65 years Reference Reference Reference Reference Reference 
Gender** 
Males 0.898 
(0.777,1.038) 
 
1.175 
(0.913,1.513) 
0.686** 
(0.521,0.902) 
0.758 
(0.425, 1.351) 
1.119 
(0.753, 1.662) 
Females Reference Reference Reference Reference Reference 
Race** 
Blacks 
 
0.476** 
(0.377,0.601) 
0.415** 
 (0.271,0.636) 
0.297** 
(0.169,0.523) 
0.575 
(0.316,1.039) 
0.573 
(0.316,1.039) 
Asians 0.859 
(0.454,1.626) 
0.925 
(0.366,2.337) 
0.128** 
(0.017,0.983) 
0.983 
(0.129,7.481) 
2.658 
(0.871,8.113) 
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Multiple Races 
reported 
0.804 
(0.521,1.241) 
0.977 
(0.357,2.673) 
0.384 
(0.139,1.063) 
0.276 
(0.038,2.028) 
2.725** 
(1.140,6.511) 
Whites Reference Reference Reference Reference Reference 
Marital Status** 
Widowed 
 
0.891 
(0.667,1.192) 
1.166 
(0.745,1.824) 
0.779 
(0.454,1.335) 
1.070 
(0.469,2.439) 
1.217 
(0.285,5.196) 
Divorced 
 
0.817 
(0.674,0.991) 
1.432** 
(1.013,2.025) 
1.027 
(0.725,1.456) 
1.043 
(0.541,2.013) 
2.412** 
(1.416,4.108) 
Separated 
 
0.823 
(0.572,1.184) 
0.772 
(0.346,1.721) 
0.561 
(0.256,1.229) 
0.461 
(0.098,2.178) 
1.694 
(0.443,6.470) 
Never Married 
 
0.907 
(0.744,1.106) 
 
1.257 
(0.911,1.733) 
0.854 
(0.583,1.252) 
1.396 
(0.646,3.018) 
2.775** 
(1.646,4.680) 
Married Reference Reference Reference Reference Reference 
Education** 
No education 
 
0.210** 
(0.060,0.737) 
0.750 
(0.180,3.127) 
0.088** 
(0.012,0.668) 
N/Ab 0.072** 
(0.009,0.532) 
Elem/ Mid 
School 
0.593** 
(0.431,0.814) 
0.506** 
(0.300,0.855) 
0.492** 
(0.283,0.858) 
1.728 
(0.731,4.087) 
0.697 
(0.259,1.871) 
High school  
 
0.838** 
(0.722,0.974) 
0.626** 
(0.472,0.830) 
0.584 
(0.433,0.788) 
0.818 
(0.442,1.514) 
0.759 
(0.480,1.199) 
5+ Years College  1.094 
(0.833,1.437) 
 
1.835** 
(1.194,2.821) 
0.851 
(0.511,1.417) 
1.143 
(0.374,3.497) 
2.183** 
(1.210,3.936) 
≤ 4 Years College Reference Reference Reference Reference Reference 
Employment status** 
Employed 
 
1.378** 
(1.149,1.652) 
 
0.960 
(0.695,1.327) 
0.804 
(0.570,1.133) 
0.518** 
(0.284,0.945) 
0.520** 
(0.303,0.892) 
Unemployed Reference Reference Reference Reference Reference 
Incomec  
Low income 
 
1.184 
(0.933,1.503) 
1.007 
(0.676,1.500) 
0.833 
(0.489,1.416) 
0.496 
(0.216,1.140) 
0.776 
(0.428,1.406) 
High income 1.042 
(0.845,1.285) 
0.946 
(0.663,1.350) 
1.251 
(0.875,1.788) 
1.099 
(0.469,2.573) 
1.560 
(0.821,2.966) 
Middle class 
income 
Reference Reference Reference Reference Reference 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin-
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants 
MA* - Miscellaneous Agents 
aThe reference class for therapy was getting no antidepressants/pharmacotherapy at all 
** - Significant results 
b - N/A – Not applicable, since there were almost no patients in that group and the sample size 
for that cell was < 5, the OR obtained for that particular group were absurd  
c- Low defined as income <100% FPL (<$12,060), middle class defined as income between 
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
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Type 3 analysis effects of multinomial logistic regression suggested that all the 
sociodemographic factors, except income, were significantly associated with the class of 
antidepressant/psychotherapy. The odds ratios suggested that age, employment and education 
were the most significantly associated factors. The percentages of those who are in that 
particular sociodemographic characteristic across the classes of antidepressants/ psychotherapy 
are represented graphically in Figure 7.  
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             Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI -   Serotonin-  
             Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants 
             MA* - Miscellaneous agents 
 
Figure 7: Most significantly associated sociodemographic characteristics 
  
As seen from the graphs and the findings above, SSRI and psychotherapy have a higher 
percentage of people in the age group of 18-44 years where as all the other groups have a higher 
percentage of people in the age group of 45-65 years. Looking at the employment status, SSRI 
and SNRI have a higher proportion of employed people whereas other groups have a higher 
proportion of unemployed people. On comparing the education received in every group, it was 
observed that SNRI had the highest proportion of people who completed college where as all 
others had highest proportion of people who completed high school. 
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Section 3.3: Discussion 
 
 The study thus suggested that in majority of cancer patients in the US, depression was 
untreated. Out of those treated, antidepressants were prescribed more frequently (32%) than 
psychotherapy (15%). SSRI was the most frequently prescribed class of antidepressant with or 
without psychotherapy followed by miscellaneous agents. Around 7.25% patients were 
prescribed psychotherapy and an antidepressant both. Some antidepressants were also 
prescribed in combination with one another. SSRI along with a miscellaneous agent was the 
most commonly prescribed combination of antidepressants. The finding of SSRI being the most 
commonly prescribed antidepressant was consistent with the findings found in the previous 
literature where, prescribing of SSRI occurred in most of the patients, along with SNRI.18,21 
However, one of these studies was conducted only in ambulatory cancer patients18 and the other 
one was not in general population.21 Also, with respect to antidepressants, exposure to 
SSRI/SNRI was the only outcome considered and comparison to other classes was not 
considered. In our study, it was also found that out of all the comorbidities included, arthritis 
and high blood pressure were the most commonly associated along with cancer and depression 
and most of the people had two comorbidities associated. These were consistent with the 
findings in the literature, where a majority of patients also reported asthma.30,39 
The quantity of prescribed drugs and the days supplied per prescription were not found 
to be significantly different from one another in this study across the classes of antidepressants. 
However, numerically, the quantity was found to be lowest whereas the days supplied per 
prescription were found to be the highest for SSRI as compared to other antidepressant classes. 
Higher quantities of SSRI were reported to be associated with abnormal heart rhythms, which 
could be the reason for the quantity of SSRI prescribed being lower. 41 In addition, the frequency 
of dosing was lower (usually once per day as opposed to 2 times in a day) which could be the 
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reason for days supplied being maximum for SSRI.41 Hence, the findings were in compliance 
with the reported dosing requirements for SSRI. 
 The trends in antidepressant use suggested that throughout the study period SSRI was 
the most frequently prescribed class. The use of miscellaneous agents and psychotherapy has 
eventually increased. The spike in the prescription of SNRI in the year 2008 could be because 
of FDA approval of Desvenlafaxine and some other SNRI with lower side effects.42 The 
findings of increase in SSRI use were consistent with the findings of a previous study conducted 
by Kantor et al.43 This study however, looked at the trends in overall prescription of SSRI only 
from 1999 to 2012 in general population.43 There have been some articles discussing side effects 
of TCA. These are higher than those associated with other classes, TCAs are also associated 
with many drug-drug interactions and hence their use has gone down over a period of time and 
if prescribed, the patients have to be thoroughly monitored.44-47 
On comparing the sociodemographic factors, it was found that all of them individually 
were significantly associated with the class of antidepressant/psychotherapy. On conducting for 
other factors, income was found to be non-significant. Age, employment status and education 
were found to be the most significant factors. It was suggested that, people who were above 65 
years of age were less likely to receive any therapy as compared to those who were below 65 
years. This is consistent with the past findings of a study where patients <55 years were more 
likely to receive any antidepressant. However, as mentioned earlier this study only consisted of 
ambulatory cancer patients and did not compare various classes of 
antidepressants/psychotherapy.18 A study conducted by Waitzfelder et al. has also suggested 
that patients aged > 60 years had lesser odds of initiating depression treatment. However, this 
study was in general population, and there has not been any other study looking specifically at 
cancer patients.48 Studies have shown that females are more likely to be treated for depression 
than males, this complies with the regression results of our study.49 Those who were employed 
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were more likely to receive SSRI and less likely to receive any other 
antidepressant/psychotherapy as compared to unemployed.  
 There are several limitations for this study. Firstly, it was a retrospective cross-sectional 
study and hence causality could not be assigned. The associations found with the 
sociodemographic factors could not be proven to be true over a longitudinal duration. In 
addition, it is possible that some patients were later switched to another class of 
antidepressant/psychotherapy, different than the one to begin with or the one that was reported 
in MEPS, these would not be captured in the dataset, since it was not longitudinal. Also, since 
the date of prescription fill was not captured under MEPS. It is possible that some patients were 
switched within 3 months (one round) to another class of antidepressant but in our study, they 
were captured as combinations of antidepressants. Secondly, the prescription of any class of 
antidepressant or psychotherapy and the demographics associated with each could also depend 
on the stage of cancer which due to the data source limitation could not be controlled. Thirdly, 
since the survey was patient-reported there could also be some recall bias involved. 
 Despite the limitations stated above, this study adds to the past literature by providing 
certain novel findings. Patterns of use across classes of antidepressants/ psychotherapy or the 
predictors associated with each class had not been explored amongst cancer patients with 
depression using a nationally representative sample in the past studies. A study conducted by 
Fisch et al. identified the predictors of antidepressant use, however, if these persist across all 
the antidepressant classes and psychotherapy or differ had never been studied.18 This study 
states that these predictors differ by classes, which increases the significance of our results. In 
addition, prescription trends have been identified for antidepressants in general, this study adds 
more to it by looking at trends per class of antidepressant and also comparing it with 
psychotherapy.17 This study also produces a framework for conducting future studies where, 
significant sociodemographic factors and predictors identified could be studied in depth. 
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CHAPTER IV: SPECIFIC AIM II 
 
Aim 2: To compare costs and healthcare utilization (office-based visits) of cancer patients 
across different classes of antidepressants in the US 
A: To compare the prescription medicines expenditures, overall costs and out of pocket 
expenses of cancer patients with comorbid depression across different classes of 
antidepressants 
B: To compare office-based visits with the expenses related to these across cancer 
patients along with comorbid depression classified based on the class of antidepressants 
Section 4.1: Methods 
Data source and study design: 
 As mentioned above, it was a cross-sectional retrospective study conducted using 
Medical Expenditure Panel Survey. For this specific aim, along with full year consolidated files 
for demographics and medical condition files for sample selection, prescription medicine files 
and office-based visits files were mainly used to identify the costs associated with each of the 
antidepressant class and psychotherapy. The study sample was same as specific aim 1 with 
17,671 patients diagnosed with cancer along with a comorbid depression condition. 
Variables: 
Demographics and controlling factors: 
 Aim 1 identified that almost all the sociodemographic characteristics were associated 
with the use of antidepressants. Age, gender, race, marital status, education, employment status 
and income were thus the demographic factors that were obtained from the full year 
consolidated files, were recoded as mentioned in aim 1, and were controlled for while comparing 
costs along with the associated comorbidities. The study also controlled for the overall health 
status of the patients since that could affect the frequency of dosing of antidepressants and some 
cost and utilization outcomes across all the groups. This variable was obtained from the full 
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year consolidated files as well. MEPS captures the overall health status of the patients into 5 
main categories namely: “excellent”, “very good”, “good”, “fair” and “poor”. It is a variable 
captured from the short form-12 version 2 (SF-12), self-assessment questionnaire (SAQ). 
Prescription medicine costs: 
 The costs associated with prescription medicines per purchase/fill were captured from 
the prescription medicines files from January 2005 to December 2015. MEPS reports the total 
amount per patients and the sources of payment for the same. These costs were associated with 
each prescription fill per month. For the prescription medicine costs purposes, psychotherapy 
alone was not considered as a treatment arm, since they did not have any antidepressants 
prescribed. The costs were thus compared against the 4 major classes of antidepressants and 
those who were prescribed psychotherapy and antidepressants both. Other than the total costs, 
the amount paid out of pocket and by private insurance was also compared across these classes, 
since these two were the major sources of payments identified. New variables were created to 
indicate the patients who paid out of pocket entirely and for those who paid using out of pocket 
and private insurance both. Other sources of payment such as Tricare, Veterans Insurance, other 
state and local government insurance, Medicare and Medicaid were also included to assess the 
proportion of patients who used these as their sources of payment. 
Office-based visits frequency and costs: 
 Similar to prescription medicines costs, similar variables were obtained from the office-
based visits files. As mentioned above, psychotherapy visits were identified by using modified 
clinical classification codes for office-based visits (657-psychotherapy/mental counseling 
visits), ‘Type of Medical person the patient talked to on the visit’ (10 = Psychologist) and ‘Best 
category for care the patient received on visit’ (4 = Psychotherapy/Mental Health Counseling). 
The frequency/number of visits were identified across the classes of antidepressants. Other 
categories for office-based visits like general checkup, treatment/diagnosis purposes which were 
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used the most were also identified across the classes of antidepressants. The costs associated 
with these visits, mainly psychotherapy, were obtained from the office-based visits files from 
January 2005 to December 2015. The costs captured by MEPS were the costs per visit. The 
sources of payment for these visits were also identified. Similar to prescription medicines, out 
of pocket and private insurance were the two main sources of payment. New variables in this 
case were created too, indicating those who paid entirely out of pocket and those who paid using 
private insurance and out of pocket both. Variables for other sources such as Tricare, Veterans 
insurance, other state and local insurance, Medicare and Medicaid were also used to assess the 
proportion of patients who used these sources of payments. For aim 2B, the costs and the 
frequency of psychotherapy visits were compared across 5 main classes: SSRI, miscellaneous 
agents, SNRI, TCA and psychotherapy only.  
Statistical Analyses: 
 All the analyses for this aim, was conducted on patient-level files created by 
summarizing the event-level files. The costs were summarized per patient using PROC 
MEANS. In order to summarize the office-based visit categories per patient, PROC 
TRANSPOSE was used. Means were used to summarize total prescription costs and total costs 
per visits across different classes of antidepressants. Frequencies/ proportions were used to 
calculate the number of psychotherapy visits across classes of antidepressants. While calculating 
means for out of pocket costs and private insurance, non-positive values were excluded to avoid 
the skewing of mean.  There were no non-positive values for total costs since all the patients 
had some costs, however there were non-positive zero out of pocket (15% patients) and private 
insurance (9% patients) prescription costs and non-positive zero out of pocket (7% patients) and 
private insurance (11% patients) office-based visit costs based on the patient’s source of 
payment. The means were calculated separately for those who paid out of pocket completely 
and for those who paid using both the sources namely, by private insurance and by out of pocket. 
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These means were calculated by restricting the analyses to patients who were identified using 
new variables (indicating if they paid out of pocket entirely or by using both the sources). These 
means (out of pocket only, out of pocket when accompanied by private insurance and out of 
pocket and private insurance both) were compared using graphs. While calculating costs for 
office-based visits, only patients with psychotherapy as an office-based visit were included. 
Those who had general checkups and treatment as reasons for office-based visits were excluded 
so the costs obtained could be associated with psychotherapy alone. ANOVA approach was 
used to conduct unadjusted analyses and to assess if there is a difference in total mean costs 
across antidepressant classes. All the means calculated were weighted using PROC 
SURVEYMEANS. In order to conduct adjusted regression analyses, PROC GLM was used. 
The distribution of total cost was non-normal and it had unbalanced variances, generalized linear 
model was thus used to conduct the analyses. Adjusted costs were then calculated by 
exponentiating the parameter estimates obtained from the generalized linear model using the 
log link function. PROC GLM was also used to conduct regression analyses on costs paid out 
of pocket and by private insurance. The GLM model used for all the costs was as follows: 
Ŷ = β0 + β1 . Age + β2 . Gender +  β3 . Race+ β4 . Marital Status + β5 . Education +  
       β6 .  Employment Status + β7 . Income +  β8 . Overall Health Status + β9 . Comorbidities +  
       β10 . Number of comorbidities + β11 . Antidepressant/Psychotherapy prescribed+ Ɛa 
 
Ŷ- Total prescription/ office-based visits/out of pocket/ private insurance costs 
  All the analyses were conducted at a significance level of 0.05. The hypothesis tested in 
this analysis was that the prescription and office-based visit costs would differ significantly 
across the groups.  The analyses were conducted using SAS v9.4 and MS Excel 2016 was used 
to plot graphs. 
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Section 4.2: Results 
 
Aim 2A: To compare the prescription medicines expenditures, overall costs and out of 
pocket expenses of cancer patients with comorbid depression across different classes of 
antidepressants 
To assess the economic burden on cancer patients mainly because of depression, 
prescription and office-based visit costs were compared across different classes of 
antidepressants and psychotherapy. The results for mean prescription costs are summarized in 
Table 10. 
Table 10: Per fill total prescription costs across depression therapy classes 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin-
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants 
MA*- Miscellaneous Agents 
Both – Antidepressant and psychotherapy 
 
 The prescription costs per purchase were the highest for SNRI (mean= $132.28). These 
findings were consistent with the prices reported earlier where SNRI had the highest prices 
reported. ANOVA test suggested that the cost for SNRI and TCA differed significantly from 
each other and from all other classes at a p-value of 0.05. The source of payment for total costs 
were further studied across 4 major classes of antidepressants. Most of the share of total 
prescription cost was paid either completely out of pocket or by out of pocket and private 
insurance both. There were around 48.87%, 43.06%, 49.80%, 34.06% of patients receiving 
SSRI, miscellaneous agents, SNRI and TCA respectively who reported a combination of both 
out of pocket and private insurance as sources of patients. Around 19.29%, 13.71%, 13.25%, 
17.90% patients receiving SSRI, miscellaneous agents, SNRI and TCA respectively reported 
Therapy Class Sample 
Size 
Mean ($ per 
fill/purchase) 
Std 
Error of 
Mean 
95% CL for Mean 
SSRI 3,401 68.34 2.0812 64.23 72.44 
MA* 1,098 79.84 5.0571 69.90 89.77 
SNRI 730 132.28 6.5123 119.49 145.08 
TCA 224 39.96 3.3478 33.39 46.52 
Both 1,278 67.15 4.1117 66.94 93.10 
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only out of pocket, others reported state and local government insurance, Tricare, Veterans 
insurance or other combinations. Around 6-6.5% patients in every group also reported using 
Medicaid as a source of payment, whereas there were very few reporting Medicare. The out of 
pocket mean values (mean of positive values, excluded the patients who had non-positive costs) 
for patients who paid entirely out of pocket, the mean share of out of pocket costs when 
accompanied by private insurance and the total mean costs for patients who paid entirely using 
out of pocket and private insurance both are summarized in Figure 8. 
                  
    Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin-   
    Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants 
    MA* - Miscellaneous Agents 
     ** The share of out of pocket costs when the source of payment was out of pocket        
                   and private insurance both     
                   *** The total cost paid by private insurance and out of pocket 
                   
Figure 8: Mean costs paid out of pocket and by private insurance across classes of 
antidepressants 
 
 As seen from the findings above, all costs, except the share of out of pocket when 
accompanied by private insurance (highest for miscellaneous agents), were the highest for 
SNRI. The mean costs associated with both sources (out of pocket and private insurance) were 
similar to the means reported above in Table 10 since that was the source of payment in majority 
of patients in all the groups. As expected, the out of pocket costs were significantly lower when 
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a share was also paid by private insurance in the SSRI, SNRI and TCA groups, whereas it was 
almost the same in the miscellaneous agents group. These costs reported were mean costs 
without controlling for other factors. An adjusted regression analyses was then conducted using 
generalized linear models controlling for demographics and the overall health status. Regression 
results for total costs paid by the patients across classes of antidepressants using generalized 
linear models are summarized in Table 11.  
Table 11: Regression results for total prescription costs 
 
Predictors Estimate Standard Error t Value p-value 
Intercept* 62.20582066 24.7190825 2.52 0.0119 
Age Groups 
18-44 years -6.92739417 3.6807988 -1.88 0.0599 
>65 years -3.65931933 5.0099021 -0.73 0.4652 
45-65 years - - - - 
Gender* 
Males 12.30309422 3.3529060 3.67 0.0002 
Females - - - - 
Race 
Blacks 3.71937511 4.5828044 0.81 0.4171 
Asians -11.28274071 13.6726905 -0.83 0.4093 
Multiple races -11.17445652 9.6305885 -1.16 0.2460 
Whites - - - - 
Marital Status 
Widowed 0.36601644 5.8745367 0.06 0.9503 
Divorced -9.18654975 4.1045221 -2.24 0.0252 
Separated 0.83341885 7.5886217 0.11 0.9126 
Never married 5.89124176 4.2672297 1.38 0.1675 
Married - - - - 
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Education* 
No education -22.67872928 21.1740225 -1.07 0.2842 
Elem/Mid School -16.34956478 6.0321145 -2.71 0.0067 
High school -3.19607752 3.4618290 -0.92 0.3559 
5+ years college 5.30329548 6.2251900 0.85 0.3943 
≤4 years college - - - - 
Employment Status 
Employed -6.29026083 3.8528733 -1.63 0.1026 
Unemployed - - - - 
Incomea 
Low -3.13492511 4.8804709 -0.64 0.0599 
High 9.10056345 4.9352345 1.84 0.0652 
Middle class - - - - 
Overall Health Status 
Excellent -1.37070499 8.2432892 -1.62 0.1048 
Very good -10.32440132 6.2116093 -1.66 0.0965 
Good 0.42975078 5.6753561 1.49 0.1375 
Fair -7.40559351 5.6348821 -1.31 0.1888 
Poor - - - - 
Comorbidities 
Asthma 2.25400711 5.1539475 0.44 0.6619 
Arthritis -11.31680318 3.9533362 -0.33 0.7391 
Diabetes -8.40233433 8.4895345 -0.99 0.3223 
High blood pressure -9.85627442 5.6943373 -1.73 0.0835 
None - - - - 
 Number of Comorbidities 
2 15.64873631 13.0680208 0.43 0.6656 
≥ 3 - - - - 
Antidepressant/Psychotherapy* 
SSRI 27.82665706 19.8866508 1.40 0.1618 
MA** 30.76547665 20.6221038 1.49 0.1358 
SNRI 63.21644585 20.7578952 3.05 0.0023 
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TCA -6.33866732 23.2797759 -0.27 0.7854 
Both*** - - - - 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin- 
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants MA** - Miscellaneous 
Agents, Both*** - Antidepressant and psychotherapy 
  *Significant predictors 
a - Low defined as income <100% FPL (<$12,060), middle class defined as income    between 
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
 
 Thus, as seen from the regression results, the total mean costs per prescription increases 
when SSRI, miscellaneous agent or SNRI is prescribed as compared to both (antidepressant and 
psychotherapy) being prescribed. These findings are consistent with the mean of total 
prescription costs reported above in table 10 where the means for SSRI, miscellaneous agents 
and SNRI are higher than the mean when both the therapies are prescribed. The total adjusted 
mean costs per prescription are summarized in Table 12, and these were the highest for SNRI 
($112.92).  On regressing the costs paid out of pocket against the predictors, these increased for 
SSRI and SNRI whereas decreased for TCA and miscellaneous agents as compared to those 
who were prescribed both the therapies. On regressing the costs paid by private insurance 
against the predictors, these increased for all the classes of antidepressants as compared to both 
the therapies being prescribed. These results  
are summarized in Appendix Tables 2 and 3.  
Table 12: Adjusted per fill total prescription costs across depression therapy classes 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA*- Miscellaneous Agents 
Both – Antidepressant and psychotherapy 
 
Therapy 
Class 
Sample 
Size 
Mean ($ per 
fill/purchase) 
Std Error of 
Mean 
95% CL for Mean 
SSRI 3,397 77.06 0.332020 76.409347 77.714610 
MA* 1,072 80.84 0.724687 79.419274 82.268223 
SNRI 713 112.92 0.722216 111.502743 114.341979 
TCA 217 44.31 1.366258 41.628754 46.999902 
Both 1,139 51.35 1.644457 48.122168 54.586994 
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Aim 2B: To compare office-based visits along with the expenses related to these across 
cancer patients with comorbid depression classified based on the class of antidepressants 
Office-based visits are more common in cancer patients since they have more frequent 
general checkups and require psychotherapy or mental health counseling more often than those 
who do not have cancer. In this study, out of all the office-based visits, psychotherapy/ mental 
counseling and the costs related to these were studied in depth, since these are used frequently 
to manage depression amongst cancer patients. These costs were studied across different classes 
of antidepressants and those receiving psychotherapy alone. Table 6 above, summarizes the 
number of patients using psychotherapy along with antidepressant, which suggests that 47.39% 
(n=1282) of patients using psychotherapy use it along with an antidepressant whereas 52.60 % 
(n=1423) use it alone. Table 13 below summarizes the total number of office-based visits across 
class of antidepressants including psychotherapy the other categories. 
Table 13: Office-based visit category by class of antidepressant 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin-   
 Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
 MA* - Miscellaneous Agents 
 
 Miscellaneous agents thus had the highest percentage of patients reporting the use of 
psychotherapy/counseling in order to manage depression. General checkups, treatment purposes 
(which could either be receiving any treatment or discussing the options) and psychotherapy 
were the major reasons for office-based visits amongst cancer patients with depression. The 
other visit categories for patients receiving psychotherapy alone are reported in Figure 9. 
Visit category SSRI (n, %) MA* (n, %) SNRI (n, %) TCA (n, %)  
General checkup 1,338 (31.97) 399 (27.74) 265 (27.31) 79 (29.15) 
Treatment 1,881 (44.95) 621 (43.18) 453 (46.70) 137 (50.55) 
Psychotherapy 733 (17.51) 338 (23.50) 182 (18.76) 29 (10.70) 
Other 232 (5.54) 80 (5.56) 70 (7.21) 26 (9.5) 
Total 4,184 (100%) 1,438 (100%) 970 (100%) 271 (100%) 
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*Percentages calculated are over n=1423 (sample size for psychotherapy alone) 
Figure 9: Classification of office-based visits for those receiving psychotherapy alone 
 
  As seen from the figure above, patients receiving psychotherapy alone, also had 
some other office-based visits, majority of which were either for treatment or follow-up 
purposes. There were around 11% (n=159) patients who did not report any office-based visit 
other than that for psychotherapy/mental health counseling. The study sample was then 
restricted to patients receiving psychotherapy as an office visit only so the costs could be 
associated mainly with psychotherapy and reduce bias due to costs associated with other 
categories of visits. The total costs associated mainly with psychotherapy/counseling across the 
classes of antidepressants and with psychotherapy alone are reported in Table 14.  
Table 14: Total mean costs associated per visit across class of antidepressants and psychotherapy 
alone 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin-
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants 
MA*-Miscellaneous Agents 
17%
31%
33%
8%
11%
Office-visits categories
General Checkup Treatment Follow-up visit Other None
Combination with 
psychotherapy 
Sample 
size 
Mean 
($/visit) 
Std Error of 
Mean 
95% CL for Mean 
SSRI 713 121.42 4.8781 111.81 131.04 
MA* 254 156.15 18.3303 120.03 192.28 
SNRI 131 139.63 15.8467 108.40 170.87 
TCA 19 131.25 36.6650 58.99 203.51 
Psychotherapy alone 626 147.40 16.2409 115.33 179.48 
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These costs did not differ significantly from each other. However, miscellaneous agents 
had a slightly higher cost associated with the visit followed by psychotherapy alone. Most of 
the share of total office-based visit costs was paid either completely out of pocket or by out of 
pocket and private insurance both. There were around 39.55%, 33.85%, 44.27%, 31.58% and 
36.58% patients receiving SSRI, miscellaneous agents, SNRI, TCA and psychotherapy alone 
respectively who reported a combination of out of pocket and private insurance as sources of 
payment. Around 8.97%, 5.11%, 6.62%, 5.26% and 13.26% patients receiving SSRI, 
miscellaneous agents, SNRI, TCA and psychotherapy alone respectively reported only out of 
pocket, others reported state and local government insurance, Tricare, Veterans insurance or 
other combinations. Medicare/ Medicaid was not reported as a source of payment for 
psychotherapy/ counseling visits by any of the patients. The mean values (mean of positive 
values, excluded the patients who had non-positive costs) paid by private insurance, out of 
pocket and by private insurance and out of pocket both are summarized in Figure 10. 
 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI - Serotonin-   
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants 
      MA* - Miscellaneous Agents 
      ** The share of out of pocket costs when the source of payment was out of pocket and  
         private insurance both     
      *** The total cost paid by private insurance and out of pocket 
Figure 10: Mean costs paid out of pocket and by private insurance across classes of 
antidepressants/psychotherapy 
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 As seen from the findings above, on excluding the non-positive values, the means 
(both sources) for certain classes of antidepressants were slightly higher than the total mean 
costs reported in Table 14. All the mean costs for office-based visits were higher for those 
receiving miscellaneous agents. This was consistent with the findings above, where the total 
mean costs were the highest for miscellaneous agents. The mean cost for those paying entirely 
out of pocket were considerably higher for those receiving miscellaneous agents (mean = 
$279.75 per visit). As expected, the out of pocket costs significantly reduced in all the groups 
when accompanied by private insurance. Since, out of pocket and private insurance were the 
major sources of payment in most of the population, the trends observed for mean costs (both 
sources) were similar to that obtained for total mean costs with SSRI being associated with the 
lowest cost and miscellaneous agents being associated with the highest costs.  
Regression was conducted using total costs per visit as the outcome variable and 
regressing against the predictors including the demographic variables, overall health status, 
number and type of comorbidities. On adjusting for other factors, the class of antidepressant 
was not significantly associated with the visit cost. These results were similar to the unadjusted 
results where the cost differences were not significant across the depression therapy classes. The 
costs however numerically reduced the most for SSRI (estimate = -54.73, p-value = 0.0171) 
followed by miscellaneous agents (estimate = -25.21, p-value = 0.4075), SNRI (estimate = -
11.41, p-value = 0.7461) and TCA (estimate = -0.96, p-value = 0.9895) as compared to 
psychotherapy alone, which was consistent with the unadjusted mean costs, where the 
unadjusted costs associated with psychotherapy alone were higher than the other classes. These 
results are summarized in Appendix Table 4. Table 15 below summarizes the adjusted costs for 
office-based visits, mainly psychotherapy. 
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Table 15: Adjusted total mean costs associated per visit across class of antidepressants and 
psychotherapy alone 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA*-Miscellaneous Agents 
  On controlling for other factors, the costs associated were the highest for those 
who received psychotherapy alone where as they were lowest for those receiving SSRI. The 
trends seen in these adjusted costs were thus different on controlling for other factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Combination with 
psychotherapy 
Sample 
size 
Mean 
($/visit) 
Std Error of 
Mean 
95% CL for Mean 
SSRI 707 110.28 2.730 104.34 116.23 
MA* 247 139.42 5.778 126.83 152.01 
SNRI 129 141.20 5.755 128.66 153.74 
TCA 19 165.84 17.263 128.23 203.45 
Psychotherapy alone 619 166.39 3.488 144.79 169.92 
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Section 4.3: Discussion 
 
 It was seen from the results that the total mean prescription costs associated per month 
were the lowest for TCA and the highest for SNRI. The findings of SNRI being associated with 
highest costs were consistent with the prices reported earlier under ‘Introduction’, where SNRI 
had highest out of pocket price for 30 tablets.23 In addition, a study conducted by Khandker et 
al. also suggested that the patients who switched from an SNRI to SSRI eventually had lower 
pharmacy and medical costs.50 This study also suggested that, switching classes of 
antidepressants was rare and patients who made a switch had higher all-cause healthcare costs 
and higher depression-related costs. This study was however conducted in non-cancer patients.50 
In our study, the total mean adjusted prescription costs were higher when SSRI, miscellaneous 
agents or SNRI was prescribed as compared to prescribing any antidepressant along with 
psychotherapy. These results were consistent with the unadjusted analyses findings, where the 
costs of the above-mentioned classes were higher than that when accompanied by 
psychotherapy. These findings were in contrast to that obtained in a study conducted by Shen 
et al.51 and Alwhaibi et al.,25 where in, the costs associated with psychotherapy along with 
antidepressant or alone were higher than that associated with only antidepressant use. However, 
these were total expenditures per patient and not just prescription costs, also these studies were 
either restricted to a specific type of cancer25 or were not in cancer population at all.51 In our 
study, it was also observed that most patients reported a combination of private insurance and 
out of pocket both as sources of payment for prescription medicines. Some also reported 
Medicaid or out of pocket entirely as a source of payment. There have not been any studies prior 
to this looking at sources of payment for depression therapies amongst cancer patients with 
depression. However, American Cancer Society suggests that, most of the cancer patients report 
private insurance as their source of payment (44%) for the total costs that are incurred during 
the cancer treatment.5 A study conducted by Iadeluca et al. also suggested that prescription 
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medications and office-based visits were the main cost drivers in their cancer population, 
however they were looking at cancer in general and not depression specifically.32  
 With respect to costs associated with office-based visits mainly psychotherapy, it was 
observed that miscellaneous agents had slightly higher unadjusted costs of these visits compared 
to other classes and psychotherapy alone. Miscellaneous agents also had the highest percentage 
of patients within this group requiring psychotherapy. The adjusted costs were the highest for 
those receiving psychotherapy only without any antidepressant, these findings were similar to 
the results of a study conducted by Alwhaibi et al.,25 where psychotherapy higher associated 
costs as compared to antidepressants only. These costs for psychotherapy visits could differ 
slightly because of the type of credentials the therapist has, the cost of running the office, the 
type of practice (community mental health or private practice) or the services offered during 
these visits and the intensities of these.52 These visit costs were paid by a combination of private 
insurance and out of pocket both by most of the patients. Medicare/ Medicaid was not reported 
as a source of payment. There have not been any studies conducted yet looking at costs 
associated with office-based visits mainly psychotherapy. The results were consistent with a 
study conducted by Chung which suggested that utilization of SSRI led to a reduction in overall 
outpatient visits and other prescription drugs however, this study was not restricted to cancer 
patients and the comparison group consisted of people only taking TCA.53 There have however 
not been any studies comparing office-based visit costs across classes of antidepressants/ 
psychotherapy amongst cancer patients with depression.  
 Our study however, has certain limitations. In addition to the limitations stated above, 
certain cost specific limitations were identified. Firstly, the prescription costs associated could 
not be restricted completely to antidepressants only. The patients were also taking some other 
medicines such as painkillers, blood pressure or cholesterol medications; however, these were 
minimum and evenly spread across all the classes. Secondly, the prescription costs were 
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associated per purchase/fills per month. However, MEPS does not capture the number of fills 
associated per person in a month. The total costs thus per month could differ based on the 
number of fills that were associated with patients taking any particular medication. Thirdly, 
when office-based visit costs were compared, these could differ based on the therapist charges, 
which is subjective and could not be controlled for in the study. Finally, since the study was not 
prospective, any further changes in the therapy and thus the cost could not be tracked.  
Despite the limitations mentioned above, the study has a lot of significance. None of the 
studies conducted prior with respect to depression amongst cancer patients have looked at costs 
associated with individual therapies. This study thus adds to the literature. There have been cost 
effective analysis studies of certain non-pharmacotherapy interventions such as telecare, home 
care, inpatient care and psycho-educational interventions; however, none of them have 
compared classes of antidepressants along with psychotherapy.33,34 There have also been studies 
looking at total expenditure in cancer patients with no depression treatment versus only 
antidepressants versus only psychotherapy however, these have not looked at prescription costs 
separately or compared costs across classes of antidepressants separately.24 In addition, the 
population in some of these studies was restricted only to specific types of cancer. There have 
also been no studies looking at office-based visit utilization and the costs associated with these 
across classes of antidepressants. This study is thus novel in producing such findings and forms 
the basis for future studies to be conducted with respect to cost comparisons. Total healthcare 
costs could be studied across classes of antidepressants. Conducting future studies addressing 
the limitations above would produce more robust results which could help in guiding formulary 
or coverage decisions based on the cost findings. 
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CHAPTER V: SPECIFIC AIM III 
 
Aim 3: To compare quality of life (QOL) of cancer patients in the US with comorbid 
depression across different classes of antidepressants and psychotherapy 
A: To compare the physical and mental component score (PCS/MCS) across different 
classes in order to assess quality of life of cancer patients with comorbid depression 
B: To compare Patient Health Questionnaire – 2 (PHQ-2) scores and the frequency of 
depression obtained from Short Form version 12 (SF-12) to assess quality of life of 
cancer patients with comorbid depression 
Section 5.1: Methods 
 
Data Source and Study Design: 
As mentioned earlier, it was a cross-sectional retrospective study conducted using 
MEPS. For this aim, office-based visit files were needed for identifying psychotherapy visits. 
All the main outcome variables were captured from the full year consolidated files. Prescription 
medicine files were used to identify patients in each class of antidepressant. The sample size 
was same as the first two aims with 17,671 patients diagnosed with cancer along with a 
comorbid depression condition. 
Variables:  
Demographics and controlling factors: 
 Similar to aim 2, age, gender, race, marital status, education, employment status and 
income were the demographic factors, overall health status (from SF-12 SAQ), comorbidities 
and number of comorbidities were the variables that were controlled for in the study. All these 
variables were obtained from full year consolidated files. 
 
 
62 
 
Quality of life variables: 
 All quality of life variables were obtained from the full year consolidated files. Physical 
and Mental Component Scores (PCS and MCS) are the continuous variables captured by MEPS 
using SF-12 SAQ. The SF-12 measures eight constructs: physical functioning, role limitations 
resulting from physical health problems, bodily pain, general health, vitality (energy/fatigue), 
social functioning, role limitation resulting from emotional problems, and mental health. MEPS 
imputes these into physical and mental domains and rescales the scores with a maximum 
average of 50.28 A higher physical/mental score indicates a better functioning and thus a better 
quality of life. MCS is mainly indicative of depression and mental health, however both the 
scores were used for this study’s purposes. PCS/MCS are mainly indicative of Health Related 
QOL (HrQOL). These scores were compared across different classes of antidepressants and 
psychotherapy, the scores across the combinations of antidepressants identified in aim 1 were 
compared too. For aim 3b, PHQ-2 scores were used to assess quality of life. These were obtained 
from the patient health questionnaire. The PHQ-2 is made up of 2 items and the scores range 
from 0 to 6. A higher PHQ-2 score indicates a greater tendency towards depression. A lower 
score thus implies lower depression and hence a better quality of life. A categorical variable 
indicating the frequency of depression in a week was used too. This variable has 4 levels for the 
frequency namely: “0-Not at all”, “1-Several Days”, “2-More Than Half The Days” and “3-
Nearly Every Day”. This variable was a part of SF-12 Self-Assessment Questionnaire – 2 weeks 
(SAQ-2 Wks). The PHQ-2 scores and frequency of patients belonging to each category of 
depression frequency were compared across different classes of antidepressants, psychotherapy 
and combinations of antidepressants. 
Statistical Analyses:  
 Means were used to summarize the PCS, MCS and PHQ-2 scores. Frequencies/ 
proportions were used to identify the percentages of patients in each of the categories for the 
depression frequency variable across the classes of antidepressants. The mean scores were 
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compared across individual classes, psychotherapy alone and combinations of antidepressants. 
The unadjusted comparison was conducted using PROC ANOVA. In order to compare the QOL 
outcomes of combinations of antidepressants against the individual classes, means were 
calculated for each group. A mean PCS/MCS/PHQ-2 score was calculated for those using any 
combination of antidepressants and this was compared against the mean score of those using 
individual classes using t-test. All these means were weighted and calculated using PROC 
SURVEYMEANS. Since, the scores had a normal distribution, PROC SURVEYREG was used 
to conduct adjusted regression analyses on PCS and MCS and PHQ-2 scores. The mean PHQ-
2 scores were also compared using graphs. The model used for regression was as follows: 
Ŷ = β0 + β1 . Age + β2 . Gender +  β3 . Race+ β4 . Marital Status + β5 . Education +  
       β6 .  Employment Status + β7 . Income +  β8 . Overall Health Status + β9 . Comorbidities +  
       β10 . Number of comorbidities + β11 . Antidepressant/Psychotherapy prescribed+ Ɛa 
 
Ŷ- PCS/MCS/PHQ-2 Score 
The categorical variable for depression frequency was compared using chi-square test 
obtained from PROC SURVEYFREQ.  Adjusted analyses was carried on the same using PROC 
SURVEYLOGISTIC, by using the multinomial regression approach. The model was as follows: 
Logit (y=a*) = log    p(y=a*)     = β0 + β1 . Age + β2 . Gender +  β3 . Race+ β4 . Marital Status +  
                                1-p(y=a*)       β5 . Education + β6 .  Employment Status + β7 . Income +   
                                                                                  β8 . Overall Health Status + β9 . Comorbidities +         
                                                       β10 . Number of comorbidities +  
                                                       β11 .  Antidepressant/Psychotherapy prescribed+ Ɛa 
*-Depression frequency either not at all, several days or more than half the days (Reference – 
Nearly every day), a-Error Term 
 
All of the analyses were conducted first on individual therapy classes and later on 
combinations of antidepressants. The analyses were conducted on a patient-level file obtained 
by summarizing the scores from an events-level file. All the analyses were conducted at a 
significance level of 0.05. The hypothesis tested in this analysis was that the QOL scores and 
depression frequency would differ significantly across the groups.  SAS v9.4 was used to 
conduct the analyses and MS Excel 2016 was used for plotting graphs. 
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Section 5.2: Results 
Aim 3A: To compare the physical and mental component score (PCS/MCS) across 
different classes in order to assess quality of life of cancer patients with comorbid 
depression 
Quality of life of patients was compared across different class of antidepressants/  
psychotherapy and combinations of antidepressants using physical and mental component 
scores (PCS and MCS). The mean PCS and MCS associated with each class are summarized in 
Tables 16 and 17 respectively. 
Table 16: Mean PCS across therapy class 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA* - Miscellaneous Agents 
Both** - Antidepressant and psychotherapy 
A higher score indicates a higher QOL 
 
Table 17: Mean MCS across therapy class 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA* - Miscellaneous Agents 
Both** - Antidepressant and psychotherapy 
A higher score indicates a higher QOL     
Therapy class Sample size Mean PCS Std Error of 
Mean 
95% CL for Mean 
PCS 
No therapy 9,480 38.58 0.2129 38.16 39.03 
SSRI 3,404 41.18 0.4470 40.30 42.06 
MA* 1,099 40.76 0.6899 39.39 42.13 
SNRI 730 41.13 0.7769 39.44 42.82 
TCA 224 38.68 1.0769 38.66 39.44 
Psychotherapy 1,423 36.77 0.8525 35.72 37.93 
Both** 1,271 35.87 0.8333 34.56 36.78 
Therapy class Sample Size Mean MCS Std Error of 
Mean 
95% CL for Mean 
MCS 
No therapy 9,480 37.36 0.2126 36.94 37.77 
SSRI 3,404 37.51 0.4195 36.69 38.34 
MA* 1,099 36.76 0.6438 35.48 38.04 
SNRI 730 38.16 0.7083 36.61 39.70 
TCA 224 38.59 1.3822 36.81 39.42 
Psychotherapy 1,423 31.64 0.8737 30.87 32.35 
Both** 1,271 29.62 0.9095 27.21 31.34 
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The above unadjusted analyses suggested that, a higher mean PCS was obtained with 
SSRI, miscellaneous agents and SNRI. On comparing MCS, it was seen that a higher score was 
associated with SNRI and TCA. The PCS scores associated with psychotherapy with or without 
an antidepressant were even lower than no therapy at all. Similar results were obtained for mean 
MCS scores, along with miscellaneous agents also having a score below no therapy at all. On 
conducting unadjusted analyses using the ANOVA test, it was found that PCS and MCS for 
some groups differed significantly from the others. These significant ANOVA results for PCS 
and MCS are summarized in Appendix Figures 1 and 2 and Tables 5 and 6 respectively. 
Adjusted regression analyses was conducted controlling for demographic factors, their health 
status in general and comorbidities associated. These results are summarized in Tables 18 and 
19. 
 
Table 18: Regression results for PCS across depression therapy classes 
 
Predictors Estimate Standard Error t value p-value 
Intercept* 23.728416 0.93900531 25.27 <.0001 
Age Groups* 
18-44 years 3.874257 0.31629756 11.78 <.0001 
>65 years -1.815827 0.42259368 -4.30 <.0001 
45-65 years - - - - 
Gender 
Males 0.278189 0.25408081 1.09 0.2742 
Females - - - - 
Race 
Blacks 0.099802 0.33801221 0.30 0.7679 
Asians 1.559674 1.01718881 1.53 0.1259 
Multiple races  -0.069454 0.59215191 -0.12 0.9067 
Whites - - - - 
Marital Status* 
Widowed -0.504700 0.45096851 -1.12 0.2637 
Divorced -0.294626 0.33787106 -0.87 0.3837 
Separated 1.250402 0.82722660 1.51 0.1314 
Never married 1.449368 0.31241265 4.64 <.0001 
Married - - - - 
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Education 
No education 1.373198 1.07486621 1.28 0.2021 
School 0.408673 0.55035149 0.74 0.4582 
High school -0.228869 0.27561317 -0.83 0.4068 
5+ years college 0.623551 0.44813450 1.39 0.1648 
≤4 years college - - - - 
Employment Status* 
Employed 3.891197 0.32932964 11.82 <.0001 
Unemployed - - - - 
Income a 
Low 0.533477 0.36957637 1.44 0.1496 
High 0.001782 0.37378312 0.01 0.9962 
Middle class - - - - 
Overall Health Status* 
Excellent 27.793365 0.56299920 49.37 <.0001 
Very good 25.297794 0.47079079 53.73 <.0001 
Good 19.034358 0.42691104 44.59 <.0001 
Fair 8.211462 0.43952025 18.68 <.0001 
Poor - - - - 
Comorbidities* 
Asthma -2.231539 0.44603500 -5.00 <.0001 
Arthritis -3.056831 0.34306491 -8.91 <.0001 
Diabetes 1.611439 0.56801676 2.84 0.0048 
High blood pressure 0.917330 0.44432410 2.06 0.0396 
None - - - - 
Number of Comorbidities 
2 0.677611 1.05998349 0.64 0.5230 
≥ 3 - - - - 
Antidepressant/Psychotherapy* 
SSRI 2.297618 0.40744707 5.64 <.0001 
MA** 2.243898 1.10656492 2.03 0.0432 
SNRI 1.868457 0.62967328 2.97 0.0032 
TCA -0.280224 1.13371517 -0.25 0.8049 
Psychotherapy 2.391769 1.34158557 1.78 0.0753 
Both*** 3.832430 1.54504948 2.48 0.0135 
No therapy - - - - 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA** - Miscellaneous Agents 
Both*** - Antidepressant and psychotherapy 
*Significant predictors 
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between 
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
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Table 19: Regression results for MCS across depression therapy classes 
 
Predictors Estimate Standard Error t value p-value 
Intercept* 33.957960 1.43596729 23.65 <.0001 
Age Groups* 
18-44 years -2.067972 0.37344141 -5.54 <.0001 
>65 years 2.921289 0.54958779 5.32 <.0001 
45-65 years - - - - 
Gender 
Males -0.174395 0.35127254 -0.50 0.6198 
Females - - - - 
Race 
Blacks 0.798348 0.46221061 1.73 0.0849 
Asians -0.472144 1.27060925 -0.37 0.7104 
Multiple races  0.732625 1.01384428 0.72 0.4703 
Whites - - - - 
Marital Status* 
Widowed -0.776112 0.63059156 -1.23 0.2191 
Divorced -1.542013 0.43718346 -3.53 0.0005 
Separated -1.725167 0.89000522 -1.94 0.0532 
Never married -2.621354 0.43058545 -6.09 <.0001 
Married - - - - 
Education 
No education -0.450708 1.53321560 -0.29 0.7689 
School -0.138705 0.65117050 -0.21 0.8314 
High school -0.103938 0.34966929 -0.30 0.7664 
5+ years college 0.621971 0.58552212 1.06 0.2887 
≤4 years college - - - - 
Employment Status* 
Employed 1.638000 0.41961254 3.90 0.0001 
Unemployed - - - - 
Income a 
Low -0.303451 0.50914415 -0.60 0.5515 
High 0.853695 0.50874153 1.68 0.0941 
Middle class - - - - 
Overall Health Status* 
Excellent 18.478604 0.76617114 24.12 <.0001 
Very good 14.931983 0.64048127 23.31 <.0001 
Good 11.666374 0.59302916 19.67 <.0001 
Fair 6.477895 0.59607520 10.87 <.0001 
Poor - - - - 
Comorbidities 
Asthma 0.434419 0.52272693 0.83 0.4064 
Arthritis 0.226897 0.42508743 0.53 0.5938 
Diabetes 1.673379 0.75773470 2.21 0.0278 
High blood 
pressure 
0.450593 0.65983624 0.68 0.4951 
None - - - - 
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Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA** - Miscellaneous Agents 
Both*** - Antidepressant and psychotherapy 
*Significant predictors 
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between 
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
 
 The depression therapy class was significantly associated with PCS and MCS. It was 
observed that except TCA, PCS was higher when any kind of antidepressant/ psychotherapy 
was prescribed compared to no therapy. With MCS, it was observed that none of the 
antidepressants/ psychotherapy led to an increase in MCS as compared to no therapy at all.  
PCS and MCS were now compared across combinations of antidepressants identified 
in aim 1A. The findings of mean PCS and MCS across these combinations are summarized in 
Tables 20 and 21. 
Table 20: Mean PCS across combination of antidepressants 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA*-Miscellaneous Agents  
A higher score indicates a higher QOL 
 
 
 
 
Number of Comorbidities 
2 1.558807 0.16183439 9.63 0.7764 
≥ 3 - - - - 
Antidepressant/Psychotherapy* 
SSRI -0.671898 0.57012753 -1.18 0.0259 
MA** -1.574317 1.08475602 -1.45 0.0036 
SNRI -3.037997 1.13809892 -2.67 0.0003 
TCA -2.064295 1.89204826 -1.09 0.3955 
Psychotherapy -0.409942 1.68289385 -0.24 0.2292 
Both*** -1.178011 1.91372016 -0.62 0.0004 
No therapy - - - - 
Combinations  Sample size Mean Std Error of Mean 95% CL for Mean 
SSRI-MA* 179 40.94 1.9131 37.18 44.70 
SNRI-MA* 47 40.27 4.0428 32.32 48.22 
SSRI-SNRI 42 44.25 3.2391 37.89 50.62 
SSRI-TCA 34 37.52 2.6088 32.39 42.65 
Other Combinations 16 42.27 5.84 30.31 53.62 
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Table 21: Mean MCS across combination of antidepressants 
 
Combination of 
antidepressants 
Sample size Mean Std Error of 
Mean 
95% CL for Mean 
SSRI-MA* 179 35.74 1.6074 32.58 38.90 
SNRI-MA* 47 37.28 3.8294 29.75 44.81 
SSRI-SNRI 42 36.25 2.7947 30.76 41.74 
SSRI-TCA 34 40.65 2.7440 35.25 46.04 
Other Combinations 16 32.89 5.51 22.52 43.35 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA*-Miscellaneous Agents 
A higher score indicates a higher QOL 
 
The findings suggest that, the PCS and MCS both were higher when antidepressants 
were given in combination as compared to given individually.  The mean PCS was highest when 
SSRI was given in combination with SNRI, whereas the MCS was highest when SSRI was 
given in combination with TCA. On comparing the PCS and MCS of those who were on 
individual therapies to those who were using combinations of antidepressants, these mean scores 
were significantly higher for those who were on combinations of antidepressants at a p-value of 
0.0352 and 0.0417 for PCS and MCS respectively. Quality of life, when measured using PCS 
and MCS was higher when SSRI was given in combination with either SNRI or TCA. However, 
the differences in PCS and MCS were not significant in unadjusted analyses conducted using 
the ANOVA test. Adjusted analyses was carried similarly for combinations and the results 
obtained suggested that, PCS increased with all the combinations as compared to getting no 
combination prescribed, the maximum increase in PCS was when SSRI was prescribed with a 
miscellaneous agent (estimate=2.47, p-value=0.0182). MCS increases only when SSRI-TCA 
(estimate=2.2, p-value=0.45) was the combination prescribed as compared to getting no 
combination prescribed. The combination of antidepressants was significantly associated with 
the PCS whereas it was associated with the MCS at the significance level of 0.1. These 
regression results are summarized in Appendix Tables 7 and 8. 
70 
 
Aim 3B: To compare Patient Health Questionnaire – 2 (PHQ-2) scores and the frequency 
of depression obtained from Short Form version 12 (SF-12) to assess quality of life of 
cancer patients with comorbid depression 
In order to compare quality of life of patients across classes of antidepressants and 
psychotherapy, PHQ-2 scores and a categorical variable indicating depression frequency from 
the SF version 12 were used. Mean PHQ-2 scores across the depression therapy classes and 
proportions of patients belonging to each category of depression frequency across the classes 
are summarized in Figure 11. SSRI were associated with the lowest PHQ-2 scores (mean = 
1.7826) indicating lesser tendency towards depression. The frequency of feeling depressed was 
the lowest with SSRI too (highest percentage of patients reporting “Not at all” – 42%).  Patients 
receiving antidepressant and psychotherapy both had the highest PHQ-2 scores (mean = 2.29) 
and highest percentage (17.94%) of patients reporting “Nearly every day” for depression 
frequency. These findings thus suggest that, the highest quality of life and lowest tendency 
towards depression is associated with SSRI and the highest tendency towards depression when 
antidepressant is given along with psychotherapy. These unadjusted findings are summarized in 
figure 11. On conducting ANOVA test for PHQ-2 scores, SSRI scores differed significantly 
from psychotherapy and no therapy both. These significant results are summarized in Appendix 
Figure 3 and Appendix Table 9. Unadjusted analyses carried out for depression frequency using 
chi square was significant at a p-value of 0.0056. Adjusted regression analyses was thus 
conducted on PHQ scores (surveyreg), these results are summarized in Table 22, and depression 
frequency (multinomial logistic regression) these results are summarized in Table 23. 
Multinomial logistic regression was conducted using “3: Nearly every day” as the reference 
group for the outcome variable. 
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Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA* - Miscellaneous Agents 
Both – Antidepressants and Psychotherapy 
A higher PHQ-2 score indicates higher tendency towards depression 
Figure 11 – Mean PHQ-2 scores and depression frequency across therapy class 
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Table 22: Regression results for PHQ-2 scores across depression therapy classes 
 
Parameter Estimate Standard Error t Value Pr > |t| 
Intercept* 3.8262809 0.42733705 8.95 <.0001 
Age Groups* 
18-44 years 0.1758891 0.05330577 3.30 0.0011 
>65 years -0.2965855 0.08613440 -3.44 0.0006 
45-65 years - - - - 
Gender* 
Males 0.1137426 0.04907728 2.32 0.0209 
Females - - - - 
Race 
Blacks -0.0171856 0.07168833 -0.24 0.8107 
Asians -0.0236067 0.14913997 -0.16 0.8743 
Multiple races  0.0815454 0.16004197 0.51 0.6107 
Whites - - - - 
Marital Status* 
Widowed 0.1488145 0.09208217 1.62 0.1068 
Divorced 0.2530129 0.06095075 4.15 <.0001 
Separated 0.2978353 0.12228318 2.44 0.0153 
Never married 0.2739648 0.06652892 4.12 <.0001 
Married - - - - 
Education* 
No education -0.1088568 0.29883598 -0.36 0.7158 
School 0.1389425 0.11449242 1.21 0.2256 
High school 0.1137930 0.05271159 2.16 0.0314 
5+ years college -0.1395697 0.08117844 -1.72 0.0863 
≤4 years college - - - - 
Employment Status* 
Employed -0.3578200 0.06237240 -5.74 <.0001 
Unemployed - - - - 
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Income a* 
Low 0.1865571 0.07900060 2.36 0.0187 
High -0.1139192 0.06636350 -1.72 0.0868 
Middle class - - - - 
Overall Health Status* 
Excellent -3.1065494 0.11563765 -26.86 <.0001 
Very good -2.7051892 0.10574756 -25.58 <.0001 
Good -2.1801921 0.09885237 -22.06 <.0001 
Fair -1.2064063 0.10037303 -12.02 <.0001 
Poor - - - - 
Comorbidities 
Asthma -0.0654268 0.08188706 -0.80 0.4247 
Arthritis 0.0802863 0.06562501 1.22 0.2219 
Diabetes -0.1317421 0.11799824 -1.12 0.2649 
High blood pressure 0.0221986 0.08542314 0.26 0.7951 
None - - - - 
Number of Comorbidities 
2 0.0043501 0.21438471 0.02 0.9838 
≥ 3 - - - - 
Antidepressant/Psychotherapy* 
SSRI -0.0103671 0.05130837 -0.20 0.8400 
MA** 0.2050913 0.10252836 2.00 0.0461 
SNRI 0.3253804 0.11778651 2.76 0.0060 
TCA -0.0988881 0.18589890 -0.53 0.5950 
Psychotherapy 0.1499525 0.16325672 0.92 0.3589 
Both*** 0.2697418 0.24444909 1.10 0.2705 
No therapy - - - - 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
 MA** - Miscellaneous Agents 
 Both*** - Antidepressant and psychotherapy 
*Significant predictors  
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between 
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
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Thus, as seen from the adjusted regression results, the depression therapy class was 
significantly associated with the PHQ-2 scores at the significance level of 0.05. The PHQ-2 
scores were lower with the utilization of SSRI and TCA as compared to no therapy at all. The 
adjusted results were consistent for SSRI with unadjusted analyses where the mean PHQ-2 score 
for SSRI was lower than no therapy at all.   
Table 23: Multinomial regression results for depression frequency 
 
Predictor Depression frequency (OR, Confidence Intervals)a 
0: Not at all 1: Several Days 2: More Than Half 
the Days 
Age** 
18-44 years 0.686** 
(0.540, 0.871) 
0.851 
(0.664, 1.092) 
1.116 
(0.864, 1.443) 
> 65 years 1.845** 
(1.269, 2.682) 
1.297 
(0.910, 1.848) 
1.170 
(0.778, 1.759) 
45-65 years Reference Reference Reference 
Gender  
Males 0.712 
(0.505, 1.003) 
0.741 
(0.520, 1.055) 
0.948 
(0.640, 1.420) 
Females Reference 
 
Reference Reference 
Race  
Blacks 0.985 
(0.554,1.752) 
0.957 
(0.527,1.736) 
  2.291** 
(1.364,3.847) 
Asians 1.774 
(0.572,5.500) 
1.110 
(0.309,3.989) 
1.158 
(0.291,4.613) 
Multiple Races 2.120 
(0.647,6.948) 
1.308 
(0.425,4.019) 
2.870 
(0.896,9.190) 
Whites Reference 
 
 
Reference Reference 
Marital Status** 
Widowed 
 
0.478** 
(0.244,0.939) 
0.420** 
(0.220,0.804) 
0.657 
(0.287,1.503) 
Divorced 
 
0.513** 
(0.321,0.819) 
0.529** 
(0.339,0.827) 
0.879 
(0.519,1.491) 
Separated 
 
0.400 
(0.152,1.052) 
0.725 
(0.315,1.667) 
0.775 
(0.294,2.044) 
Never Married 
 
0.535** 
(0.331,0.867) 
0.693 
(0.420,1.144) 
1.188 
(0.174,4.029) 
Married Reference 
 
 
Reference Reference 
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Education 
No education 
 
0.836 
(0.174,4.029) 
0.604 
(0.098,3.700) 
1.050 
(0.082,13.420) 
Elem/ Mid School 
 
0.819 
(0.358,1.876) 
0.695 
(0.333,1.450) 
1.321 
(0.603,2.893) 
High school  
 
0.831 
(0.558,1.239) 
0.698 
(0.485,1.005) 
0.972 
(0.625,1.510) 
5+ Years College  1.206 
(0.576,2.526) 
1.048 
(0.504,2.180) 
0.965 
(0.404,2.308) 
≤ 4 years college Reference 
 
Reference Reference 
Employment Status** 
Employed 
 
1.959** 
(1.255, 3.060) 
1.793** 
(1.144, 2812) 
1.816** 
(1.102, 2.993) 
Unemployed Reference 
 
Reference Reference 
Income b** 
Low income 
 
0.716** 
(0.535, 0.958) 
0.750** 
(0.575, 0.978) 
0.936 
(0.711, 1.233) 
High income 
 
1.176 
(0.806, 1.715)) 
1.009  
(0.689, 1.478) 
0.965 
(0.620, 1.501) 
Middle class income Reference 
 
Reference Reference 
Overall Health Status** 
Excellent 228.761** 
(68.720, 761.51) 
28.251** 
(8.520, 93.683) 
4.842** 
(1.179, 19.894) 
Very good 101.589** 
(45.245, 228.098) 
24.818** 
(11.797, 52.210) 
5.649** 
(2.577, 12.385) 
Good 24.931** 
(12.851, 48.365) 
10.740** 
(6.001, 19.22) 
2.670** 
(1.493, 4.77) 
Fair 4.562** 
(2.407, 8.649) 
4.316** 
(2.491, 7.479) 
1.949** 
(1.118, 3.396) 
Poor Reference 
 
Reference Reference 
Comorbidities  
Asthma 0.810 
(0.477, 1.374) 
0.708 
(0.410, 1.223) 
0.552 
(0.279, 1.092) 
Arthritis 1.206 
(0.721, 2.018) 
0.971 
(0.597,1.577) 
0.871 
(0.490, 1.549) 
Diabetes 2.709 
(0.162, 6.314) 
1.655 
(0.737, 3.718) 
1.705 
(0.636, 4.572) 
High blood pressure 1.031 
(0.544, 1.953) 
0.765 
(0.391, 1.498) 
0.899 
(0.423, 1.912) 
None Reference 
 
Reference Reference 
Number of Comorbidities  
2 0.244 
(0.041, 1.468) 
0.221 
(0.049, 1.003) 
0.182 
(0.029, 1.133) 
≥ 3 Reference 
 
Reference Reference 
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Antidepressant/ Psychotherapy  
SSRI 2.318 
(0.654, 8.224) 
0.752 
(0.236, 2.399) 
1.824 
(0.532, 6.257) 
MA* 1.547 
(0.403, 5.935) 
0.688 
(0.204, 2.321) 
1.641 
(0.439, 6.129) 
SNRI 1.371 
(0.350, 5.371) 
0.596 
(0.168, 2.107) 
1.758 
(0.431, 7.161) 
TCA 2.365 
(0.507, 11.044) 
0.695 
(0.163, 2.969) 
1.568 
(0.371, 6.618) 
Psychotherapy 1.580 
(0.368, 6.788) 
0.774 
(0.210, 2.847) 
1.122 
(0.273, 4.605) 
Both*** Reference Reference Reference 
 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
*MA = Miscellaneous Agents 
a The reference class for depression frequency was 3: Nearly every day 
** - Significant results 
Both*** - Antidepressant and Psychotherapy 
b - Low defined as income <100% FPL (<$12,060), middle class defined as income between 
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
 
Thus, as seen from the multinomial regression results, on adjusting for other factors, 
antidepressant/ psychotherapy class was not significantly associated with the frequency of 
depression. However, numerically it was found that, as compared to both the therapies 
(antidepressant and psychotherapy) being prescribed, all the classes had a higher likelihood of 
reporting either “not at all” or “more than half days” of depression (OR>1). 
Mean PHQ-2 scores and depression frequency were then compared across combinations 
of antidepressants, since, PCS and MCS suggested that a better quality of life was associated 
with combinations. SSRI with SNRI was the combination associated with the lowest PHQ-2 
scores (mean = 1.13) indicating lesser tendency towards depression. The findings of  
significantly lower PHQ-2 scores (p-value = 0.0214) being associated with combinations of 
antidepressants as compared to individual classes were consistent with the results suggested by 
PCS and MCS. The frequency of feeling depressed was the lowest with SSRI and TCA as a 
combination (highest percentage of patients reporting “Not at all” – 46.87%) with SSRI-SNRI 
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combination having the lowest percentage (8.10%) of patients reporting “Nearly every day” 
depression. These findings thus suggest that, the highest quality of life and lowest tendency 
towards depression is associated with SSRI – SNRI or SSRI - TCA. These unadjusted findings 
are reported in Figure 12. ANOVA results for unadjusted analyses suggested that the differences 
in PHQ-2 scores across the combination groups were not significant. Chi-square test for 
depression frequency could not be conducted since one of the categories had a sample size of 
less than 5, hence Fisher’s exact test was conducted which suggested that, the depression therapy 
class was not significantly associated with the depression frequency (p-value=0.713).  
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Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA* - Miscellaneous Agents 
Both – Antidepressants and Psychotherapy 
A higher PHQ-2 score indicates higher tendency towards depression 
 
Figure 12 – Mean PHQ-2 scores and depression frequency across combinations of 
antidepressants 
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Adjusted analyses was then conducted to evaluate if the combinations of antidepressants were 
associated with PHQ-2 scores (surveyreg) or depression frequency (multinomial logistic 
regression) on accounting for other factors. Results for these are summarized under Appendix 
Tables 10 and 11 respectively. On controlling for other factors, the combinations of 
antidepressant were not significantly associated with the PHQ-2 score at a p-value of 0.7665. 
Numerically, all the combinations except SNRI - Miscellaneous Agents (estimate = 0.5534, p-
value = 0.2659) and SSRI-SNRI (estimate = 0.0905, p-value = 0.8032) reduced PHQ-2 scores 
as compared to not getting any combination of antidepressant prescribed. The combinations 
were however significantly associated with the depression frequency on controlling for other 
factors. Patients receiving ‘other combinations’ (TCA either with a miscellaneous agent or 
SNRI) were less likely to report more than half days of depression as compared to no 
combinations prescribed. 
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Section 5.3: Discussion 
 
 The study thus suggested that individually SSRI, miscellaneous agents and SNRI were 
associated with a higher mean PCS whereas SNRI and TCA were associated with a higher mean 
MCS. Psychotherapy with or without an antidepressant was associated with lower scores. These 
findings were consistent with the study findings in the literature that suggested pharmacotherapy 
had higher effectiveness than psychotherapy. A study conducted by Siddique et al. suggested 
that amongst depressed women with moderate baseline depression, pharmacotherapy was 
superior to psychotherapy.54 In women with severe depression, psychotherapy was superior, 
however after 12 months. This study was however not restricted to cancer population, also, the 
psychotherapy that they looked at was cognitive-behavioral therapy or community mental health 
service and not necessarily an office-based physician visit.54 A study conducted by Vyas et al. 
suggested that amongst cancer patients with depression, the mean MCS score was lowest among 
those who received psychotherapy with or without antidepressants compared to those receiving 
antidepressants only and those with no reported use of either.30 Similar results were replicated 
in our study. The study conducted by Vyas et al. however, did not look at classes of 
antidepressants or combinations of antidepressants separately. Adjusted regression analyses in 
our study suggested that, PCS was higher with any kind of antidepressant/psychotherapy except 
TCA compared to no treatment at all. MCS however was not higher for any of therapy classes 
as compared to no treatment at all. It was also found that PCS and MCS both were even higher 
when the antidepressants were used in combination with each other, with SSRI-SNRI producing 
the highest PCS and SSRI-TCA producing the highest MCS. It was thus suggested that, using 
SSRI either in combination with SNRI or TCA or individually produced the highest quality of 
life. The results of SSRI being associated with a higher QOL were consistent with a study that 
compared pharmacotherapy involved in treating depression. However, this study did not include 
psychotherapy and only included monotherapy, excluding combinations of antidepressants. The 
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study was also not restricted to cancer population.55 There have been studies comparing the 
effectiveness and suggesting that pharmacotherapy is more effective than psychotherapy.55,56 
These were however, not necessarily amongst cancer patients55 or necessarily did not look at 
quality of life as an outcome measure for effectiveness.56 
 On comparing the PHQ-2 scores and depression frequency from SF-12, it was observed 
that, SSRI had the lowest PHQ-2 score indicating lesser tendency towards depression, the 
depression frequency was also reported to be low by maximum patients in the SSRI group. In 
addition, combinations of antidepressants had even lower PHQ-2 scores, with SSRI-SNRI 
having the lowest score. The frequency of depression was reported to be low with most of the 
patients in the SSRI-TCA group. Thus, similar results were obtained for quality of life by both 
these methods, where SSRI was suggested to be superior to others, individually or in 
combination with either an SNRI or a TCA. These findings were consistent with the literature, 
where a study conducted by Mills et al. suggested that the PHQ scores and depression frequency 
improved after antidepressant initiation.57 However, in this study, antidepressants were not 
compared against psychotherapy. In addition, this study was not restricted to cancer patients. 
The results of SSRI being associated with the highest QOL and relatively lower prescription 
and office-based visit costs (from specific aim 2) also align with the results of a study that has 
already been conducted which suggests that a lower financial burden usually leads to a higher 
QOL and lower tendency towards depression.6 
 In addition to the limitations stated above, there were certain QOL limitations identified.  
One of the major limitation of the study is selection bias. The reason for lower MCS with the 
treatment groups or the lower PCS/MCS and higher PHQ-2 scores with psychotherapy could be 
due to the difference in population across classes of antidepressants and the baseline scores 
being worse to begin with as compared to others. Presence of such selection bias affects the 
validity of the results obtained above. Secondly, quality of life is a subjective term and the 
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scores/frequency of depression could vary based on personal preferences. Thirdly, the quality 
of life could be associated with the cancer condition and not depression, which is a common 
limitation of studies looking at comorbidities. However certain cancer characteristics such as, 
the type of cancer, remission state and other comorbidities associated were looked at in the study 
which would help in reducing the bias but due to maximum missing values this effect would be 
minimum. Certain types of cancers have higher survival rates and depression levels in these 
patients could be different as compared to those with lower survival rates.58 Also, some cancers 
have certain effects on the endocrine and hormonal system which would present depression 
differently in these.59 Due to the missing values, these effects of type of cancer could not be 
studied. Moreover, the data being cross-sectional, it was not possible to track the patients. 
Depression treatment could have long-term effects and could improve quality of life after a long 
duration; however, this could not be tracked due to data limitations and the study being cross-
sectional. In addition, certain antidepressants were reported to have interactions with certain 
chemotherapeutic drugs which could lower the quality of life of certain specific cancer patients 
mainly breast cancer patients.60 However, this could not be tracked because of the lack of 
available data. Finally, the stage of cancer could also have some effect on the quality of life; 
however, this is not captured by MEPS and hence was not controlled for in the study.  
 Despite of these limitations, the findings add a lot to the literature. None of the studies 
so far have looked at quality of life associated with separate classes of antidepressants or 
combinations of antidepressants. Studies so far have compared antidepressants as a whole with 
psychotherapy or no treatment at all; however, none of them have looked at individual classes. 
This is the first study that also compares the quality of life associated with combinations of 
antidepressants and suggests that higher quality of life scores are associated with combinations 
of antidepressants as compared to using antidepressants individually. These findings form the 
basis for future studies to explore the combinations even further, since these were associated 
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with a higher QOL. However, a higher QOL could also be associated with higher side effects 
which could be explored in future studies.  As stated above, our study has limitations due to 
selection bias involved, future studies could address this limitation by using a longitudinal 
dataset or matching the patients and produce more robust findings. Our study is hypothesis 
generating for such future studies.  On achieving more robust results, the patient-reported QOL 
findings could also provide certain guidance to clinicians to manage depression amongst cancer 
patients more efficiently. 
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CHAPTER VI: CONCLUSIONS AND FUTURE RESEARCH 
 
Section 6.1: Conclusions 
Our study examined the patterns of use, sociodemographic characteristics, prescription 
medicine costs, office-based visit costs and QOL associated with the utilization of 
antidepressants and psychotherapy amongst cancer patients with a comorbid depression 
condition. These factors were studied across all the classes of antidepressants/ psychotherapy 
and were compared against each other. It was found that in a majority of patients had untreated  
depression (53.64%). Amongst those receiving antidepressants, SSRI was the most commonly 
prescribed antidepressant with or without psychotherapy. Psychotherapy was also prescribed to 
many patients with or without any antidepressant. The patterns of use were similar across all 
the classes of antidepressants. As suggested by the trends observed throughout the study period, 
the use of psychotherapy and miscellaneous agents has eventually increased with SSRI still 
being the most frequently prescribed antidepressant class. On identifying the sociodemographic 
characteristics, age, employment status and education were found to be the most significantly 
associated predictors of receiving any particular class of antidepressant/psychotherapy. Age and 
employment status were significant even in most of the adjusted analyses, where people below 
65 years of age and who were employed had a higher PCS and a lower PHQ score. MCS was 
however higher in those above 65 years of age and employed. These were not significantly 
associated with total prescription medicine or office-based visit costs. 
Comparing the total prescription medicine and office-based visit costs, it was found that, 
the adjusted mean prescription costs per purchase were the highest for SNRI ($112.92 per 
fill/purchase) with out of pocket and private insurance being the sources of payments in majority 
of the patients. The adjusted office-based visit costs mainly associated with psychotherapy were 
the highest for those receiving psychotherapy only without any antidepressant (mean = 
$166.39/visit). The sources of payment were similar to those of prescription medicine costs. 
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Some other major office-based visits identified along with psychotherapy were general checkup, 
treatment and follow-up visit. 
 Quality of Life as measured by PCS was the highest for SSRI (mean = 41.18), whereas 
MCS was the highest for TCA (mean = 38.59). Psychotherapy with or without any 
antidepressants was associated with a lower PCS and MCS. Both the PCS and MCS were higher 
when the antidepressants were prescribed in combination with one another, with SSRI-SNRI 
associated with the highest PCS (mean = 44.25) and SSRI-TCA associated with the highest 
MCS (mean = 40.65). The PHQ-2 scores and depression frequency also suggested using 
antidepressants in combinations. SSRI-SNRI was associated with the lowest PHQ-2 score 
(mean = 1.13) indicating a lower tendency towards depression. It was thus suggested that the 
QOL was the highest when SSRI was given in combination with either SNRI or TCA by all the 
measures. As mentioned above, these results could however involve selection bias since the 
groups were not randomized and were non uniform.  
 As stated above, these results would further help policy makers and clinicians in guiding 
their decision regarding depression management amongst cancer patients. It also provides a 
framework for further studies to be conducted which could explore the outcomes associated 
with SSRI more, since as identified in this study, it is associated with a lower cost and higher 
QOL. Finally, it is one of the first studies looking at patterns of use, costs and QOL across 
classes of antidepressants/ psychotherapy amongst cancer patients with depression in the US in 
a nationally representative population and hence has high generalizability. 
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Section 6.2: Future Research 
 Based on the results obtained in our study, further hypotheses can be generated in order 
to carry out a cost-effective or a cost-benefit analysis study comparing antidepressant (identified 
in our study that they have higher costs and higher QOL) to psychotherapy. The current study 
was cross-sectional and there were certain other data limitations to it as mentioned above, which 
can be overcome by using a longitudinal database like SEER. Family history of depression was 
identified as one of the predictors for antidepressant use by a study.18 This could not be studied 
using MEPS due to data limitation but can be explored further using another dataset or 
conducting a primary research study. In addition, costs/outcomes associated with combinations 
of antidepressants can be explored further, since as suggested by this research, they are 
associated with a higher QOL. Although, combinations of antidepressants could also be 
associated with higher side effects resulting into higher hospital visits and utilization, which 
could also be studied further. Since, antidepressants can have long-term effects, future studies, 
with the help of an appropriate dataset or by collecting data primarily can look at some of the 
long-term effects and costs associated with these. 
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APPENDIX 
 
Table 1: Names of antidepressants under each class included by MEPS 
 
Class of Antidepressant Specific Names 
SSRI Fluoxetine, Paroxetine, Citalopram, Escitalopram, Sertraline 
MA* Bupropion, Vilazodone, Trazodone 
SNRI Duloxetine, Venlafaxine, Milnacipran 
TCA Amitriptyline, Imipramine, Desipramine, Clomipramine, 
Doxepin 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA* - Miscellaneous Agents 
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Table 2: Regression results for out of pocket mean 
 
Parameter Estimate Standard Error t Value Pr > |t| 
Intercept* 24.89205222 8.74675731 2.85 0.0044 
Age Groups 
18-44 years -1.50047886 1.30243726 -1.15 0.2493 
> 65 years 1.00642186 1.77273562 0.57 0.5702 
45-65 years - - - - 
Gender 
Males 2.09221651 1.18641357 1.76 0.0779 
Females - - - - 
Race* 
Blacks -5.00697489 1.62160864 -3.09 0.0020 
Asians  -10.01955001 4.83803174 -2.07 0.0384 
Multiple Races -6.01595753 3.40774864 -1.77 0.0775 
Whites - - - - 
Marital Status 
Widowed 3.24869167 2.07868341 1.56 0.1181 
Divorced -1.17190603 1.45237018 -0.81 0.4198 
Separated -0.97394564 2.68520613 -0.36 0.7168 
Never married -0.40774070 1.50994369 -0.27 0.7871 
Married - - - - 
Education 
No education -1.43296923 7.49235072 -0.19 0.8483 
Elem/ Mid School -4.67678411 2.13444176 -2.19 0.0285 
High school -3.00020914 1.22495556 -2.45 0.0143 
5+ years college -0.64547227 2.20276081 -0.29 0.7695 
≤4 years college - - - - 
Employment Status* 
Employed 1.17311514 1.36332519 3.06 0.0022 
Unemployed - - - - 
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Incomea 
Low 2.24144739 1.72693686 1.30 0.1944 
High 1.40480556 1.74631474 0.80 0.4212 
Middle class - - - - 
Overall Health Status 
Excellent -3.91695499 2.91685784 -0.66 0.5111 
Very good -1.01249562 2.19795533 -0.46 0.6451 
Good -1.76607286 2.00820408 -0.38 0.7029 
Fair -1.95592030 1.99388251 -0.98 0.3266 
Poor - - - - 
Comorbidities* 
Asthma -3.93870068 1.82370555 -2.16 0.0308 
Arthritis -7.49776796 1.39887361 -5.36 <.0001 
Diabetes -5.92353195 3.00399085 -1.97 0.0487 
High blood pressure -5.98537545 2.01492051 -2.97 0.0030 
None - - - - 
Number of Comorbidities 
2 13.12443039 4.62407154 0.68 0.4993 
≥ 3 - - - - 
Antidepressant/ Psychotherapy* 
SSRI 3.56660851 7.03681896 0.51 0.6123 
MA** -1.76813682 7.29705630 -0.11 0.9162 
SNRI 10.44893516 7.34510560 1.42 0.01549 
TCA -9.41596457 8.23746390 -0.78 0.04361 
Both*** - - - - 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
 MA** - Miscellaneous Agents 
 Both*** - Antidepressant and psychotherapy 
 *Significant predictors 
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between 
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
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Table 3: Regression results for private insurance mean 
 
Parameter Estimate Standard Error t Value Pr > |t| 
Intercept* 6.92742626 15.34217368 0.45 0.6516 
Age Groups* 
18-44 years -10.69437442 2.28452877 -4.68 <.0001 
> 65 years -13.09469435 3.10945151 -4.21 <.0001 
45-65 years - - - - 
Gender* 
Males -2.05571531 2.08101841 -0.99 0.03233 
Females - - - - 
Race 
Blacks  -1.40114029 2.84436855 -0.49 0.6223 
Asians -4.26155647 8.48610755 -0.50 0.6156 
Multiple Races -5.24204676 5.97733190 -0.88 0.3805 
Whites - - - - 
Marital Status* 
Widowed -9.99602554 3.64609658 -2.74 0.0061 
Divorced -18.60734786 2.54751730 -7.30 <.0001 
Separated -10.89525996 4.70996249 -2.31 0.0207 
Never married -11.06275973 2.64850362 -4.18 <.0001 
Married - - - - 
Education* 
No education -16.51308617 13.14189269 -1.26 0.2090 
School -14.22990611 3.74389902 -3.80 0.0001 
High school -3.88944507 2.14862266 -1.81 0.0703 
5+ years college  4.55515847 3.86373346 1.18 0.2385 
≤4 years college - - - - 
Employment Status* 
Employed -10.52912219 2.39132871 -5.24 <.0001 
Unemployed - - - - 
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Incomea* 
Low 0.03531818 3.02911860 0.01 0.9907 
High 12.75315004 3.06310819 4.16 <.0001 
Middle class -  - - 
Overall Health Status* 
Excellent 3.57859162 5.11628916 0.70 0.4843 
Very good -4.53679795 3.85530444 -1.95 0.0506 
Good 9.06168072 3.52247292 1.15 0.02489 
Fair 7.35823912 3.49735230 0.39 0.6978 
Poor -  - - 
Comorbidities 
Asthma 1.52376768 3.19885487 0.16 0.8699 
Arthritis -3.48482396 2.45368210 -0.20 0.8434 
Diabetes -19.48482396 5.26912405 -0.19 0.8434 
High blood pressure -3.33090645 3.53425381 -0.94 0.3460 
None -  - - 
Number of Comorbidities 
2 13.10729660 8.11081251 0.88 0.3809 
≥ 3 -  - - 
Antidepressant/Psychotherapy* 
SSRI 31.40857817 12.34287116 1.41 0.01585 
MA** 36.42555682 16.42555682 1.28 0.01994 
SNRI 54.34920142 12.88361866 2.67 0.0077 
TCA 5.15450675 14.44885198 0.36 0.7213 
Both*** -  - - 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA** - Miscellaneous Agents 
 Both*** - Antidepressant and psychotherapy 
 *Significant predictors 
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between 
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
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Table 4: Regression results for total mean costs associated with office-based visits across 
the depression therapy classes 
 
 
Parameter Estimate Standard Error t Value Pr > |t| 
Intercept 53.6476569 187.3324928 0.29 0.7747 
Age groups 
18-44 years -1.9655426 22.2586973 -0.09 0.9297 
> 65 years -17.5375943 47.5225233 -0.37 0.7122 
45-65 years - - - - 
Gender 
Males 11.8761283 20.6516483 0.58 0.5655 
Females - - - - 
Race 
Blacks  26.7029490 28.7576662 0.93 0.3535 
Asians -29.5338169 94.3807429 -0.31 0.7544 
Multiple Races 29.9604617 64.3155627 0.47 0.6415 
Whites - - - - 
Marital Status 
Widowed -45.9267711 50.7617867 -0.90 0.3659 
Divorced -26.7392134 26.5802324 -1.01 0.3148 
Separated -38.5364169 46.1481697 -0.84 0.4040 
Never married -3.6898327 25.4342062 -0.15 0.8847 
Married - - - - 
Education* 
No education 348.5230548 126.7031474 2.75 0.0061 
School -1.2809766 48.4710790 -0.03 0.9789 
High school -7.9406433 22.1071736 -0.36 0.7196 
5+ years college  79.3119381 36.6317060 2.17 0.0308 
≤4 years college - - - - 
Employment Status 
Employed 31.5660583 23.7834408 1.33 0.1849 
Unemployed - - - - 
 
101 
 
Income a 
Low 2.3544166 29.9792873 0.08 0.9374 
High -18.1456907 31.2543869 -0.58 0.5617 
Middle class - - - - 
Overall Health Status 
Excellent -30.1133732 52.4238654 -0.57 0.5659 
Very good -2.0131863 42.3824247 -0.05 0.9621 
Good -17.1224176 40.0574044 -0.43 0.6692 
Fair -17.4989455 39.4296601 -0.44 0.6573 
Poor - - - - 
Comorbidities 
Asthma -3.5462970 30.7966528 -0.12 0.9084 
Arthritis -26.0213489 29.3743990 -0.89 0.3760 
Diabetes -0.1337772 62.6870647 -0.00 0.9983 
High blood 
pressure 
42.1564507 37.0422598 1.14 0.2555 
None - - - - 
Number of comorbidities 
2 72.8539973 175.3242383 0.42 0.6779 
≥ 3 - - - - 
Antidepressant along with psychotherapy 
SSRI -54.7345382 22.8998066 -2.39 0.0171 
MA** -25.2182136 30.4261791 -0.83 0.4075 
SNRI -11.4613521 35.3772990 -0.32 0.7461 
TCA -0.9686245 73.6722672 -0.01 0.9895 
Psychotherapy 
alone 
- - - - 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA** - Miscellaneous Agents 
*Significant predictors 
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between 
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
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Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
No t – No therapy 
MA* - Miscellaneous Agents 
Both- Antidepressant and Psychotherapy both 
Figure 1: Distribution of PCS across depression therapy classes 
 
Table 5 – Significant ANOVA results for PCS comparison across depression therapy 
classes 
Comparisons significant at the 0.05 level are indicated by ***. 
Therapy class Difference Between 
Means 
Simultaneous 95% Confidence 
Limits 
  
3: SNRI - 0: No t a 3.6162 1.2188 6.0137 *** 
3: SNRI - 5: Psyc 6.6499 2.9946 10.3051 *** 
3: SNRI - 6: Both b 6.9709 0.7615 13.1803 *** 
1: SSRI - 0: No t 2.8004 1.6221 3.9786 *** 
1: SSRI - 5: Psyc 5.8340 2.8338 8.8342 *** 
1: SSRI - 6: Both  6.1550 0.3072 12.0028 *** 
2: TCA - 0: No t 2.1614 0.0380 4.2847 *** 
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2: TCA - 5: Psyc 5.1950 1.7134 8.6766 *** 
0: No t - 3: SNRI -3.6162 -6.0137 -1.2188 *** 
0: No t - 1: SSRI -2.8004 -3.9786 -1.6221 *** 
0: No t - 2: TCA -2.1614 -4.2847 -0.0380 *** 
0: No t - 5: Psyc 3.0336 0.1603 5.9069 *** 
5: Psyc - 3: SNRI -6.6499 -10.3051 -2.9946 *** 
5: Psyc - 1: SSRI -5.8340 -8.8342 -2.8338 *** 
5: Psyc - 2: TCA -5.1950 -8.6766 -1.7134 *** 
5: Psyc - 0: No t -3.0336 -5.9069 -0.1603 *** 
6: Both - 3: SNRI -6.9709 -13.1803 -0.7615 *** 
6: Both - 1: SSRI -6.1550 -12.0028 -0.3072 *** 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
a-No therapy 
b-Antidepressant and Psychotherapy Both 
 
 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
No t – No therapy 
MA* - Miscellaneous Agents 
Both- Antidepressant and Psychotherapy both 
Figure 2: Distribution of MCS across depression therapy classes 
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Table 6 – Significant ANOVA results for MCS comparison across depression therapy 
classes 
 
Comparisons significant at the 0.05 level are indicated by ***. 
Therapy Class Difference 
Between 
Means 
Simultaneous 95% Confidence 
Limits 
 
3: SNRI - 5: Psyc 8.1075 4.6311 11.5839 *** 
3: SNRI - 6: Both a 8.9740 3.0684 14.8795 *** 
4: TCA - 5: Psyc 7.9680 2.9894 12.9466 *** 
4: TCA - 6: Both 8.8345 1.9369 15.7320 *** 
1: SSRI - 5: Psyc 6.3814 3.5280 9.2349 *** 
1: SSRI - 6: Both 7.2479 1.6862 12.8096 *** 
0: No t b - 5: Psyc 6.3029 3.5702 9.0356 *** 
0: No t - 6: Both 7.1694 1.6686 12.6701 *** 
2: MA* - 5: Psyc 5.6476 2.3364 8.9589 *** 
2: MA* - 6: Both 6.5141 0.7042 12.3239 *** 
5: Psyc - 3: SNRI -8.1075 -11.5839 -4.6311 *** 
5: Psyc - 4: TCA -7.9680 -12.9466 -2.9894 *** 
5: Psyc - 1: SSRI -6.3814 -9.2349 -3.5280 *** 
5: Psyc - 0: No t -6.3029 -9.0356 -3.5702 *** 
5: Psyc - 2: MA* -5.6476 -8.9589 -2.3364 *** 
6: Both - 3: SNRI -8.9740 -14.8795 -3.0684 *** 
6: Both - 4: TCA -8.8345 -15.7320 -1.9369 *** 
6: Both - 1: SSRI -7.2479 -12.8096 -1.6862 *** 
6: Both - 0: No t -7.1694 -12.6701 -1.6686 *** 
6: Both - 2: MA* -6.5141 -12.3239 -0.7042 *** 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
a- Antidepressant and Psychotherapy Both 
b-No therapy 
MA* - Miscellaneous Agents 
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Table 7: Regression results for Physical Component Scores for combinations of 
antidepressants 
 
Parameter Estimate Standard Error t Value Pr > |t| 
Intercept* 23.737071 0.93949108 25.27 <.0001 
Age groups* 
18-44 years 3.544700 0.32190941 11.01 <.0001 
> 65 years -1.531427 0.41001011 -3.74 0.0002 
45-65 years - - - - 
Gender 
Males 0.327339 0.25427629 1.29 0.1987 
Females - - - - 
Race 
Blacks -0.073475 0.33992723 -0.22 0.8290 
Asians  1.399997 1.02685030 1.36 0.1735 
Multiple Races -0.087833 0.57709360 -0.15 0.8791 
Whites - - - - 
Marital Status* 
Widowed -0.526873 0.44996723 -1.17 0.2423 
Divorced -0.305923 0.33941 -0.9 0.3679 
Separated 1.25079 0.83265 1.5 0.1338 
Never married 1.43798 0.31128 4.62 <.0001 
Married - - - - 
Education 
No education 1.14764 1.05989 1.08 0.2795 
Elem/ Mid School 0.30336 0.54825 0.55 0.5803 
High school -0.2583 0.27664 -0.93 0.351 
5+ years college 0.64182 0.44502 1.44 0.15 
≤4 years college - - - - 
Employment Status* 
Employed 3.950119 0.32796056 12.04 <.0001 
Unemployed - - - - 
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Income a 
Low 0.509209 0.36687368 1.39 0.1659 
High 0.026453 0.37817921 0.07 0.9443 
Middle class - - - - 
Overall Health Status* 
Excellent 28.062420 0.55912130 50.19 <.0001 
Very good 25.481147 0.47509790 53.63 <.0001 
Good 19.138884 0.43428593 44.07 <.0001 
Fair 8.267454 0.44576231 18.55 <.0001 
Poor - - - - 
Comorbidities* 
Asthma -2.236821 0.44825096 -4.99 <.0001 
Arthritis -3.043042 0.34248529 -8.89 <.0001 
Diabetes 1.694565 0.58220957 2.91 0.0038 
High blood pressure 0.997117 0.45210909 2.21 0.0280 
None - - - - 
Number of comorbidities 
2 0.779260 1.07477781 0.73 0.4688 
≥ 3 - - - - 
Combination of antidepressants* 
SSRI-MA** 2.479085 1.04549570 2.37 0.0182 
SNRI-MA** 1.337592 1.46930357 0.91 0.3632 
SSRI-SNRI 0.079626 2.37666638 0.03 0.9733 
SSRI-TCA 0.112497 1.43652840 0.08 0.9376 
Other combinations 0.403784 3.08942656 0.13 0.8961 
None - - - - 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA** - Miscellaneous Agents 
*Significant predictors  
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between the 
range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
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Table 8: Regression results for Mental Component Scores for combinations of 
antidepressants 
 
 
Parameter Estimate Standard Error t Value Pr > |t| 
Intercept* 34.089138 1.43485949 23.76 <.0001 
Age Groups* 
18-44 years -2.076411 0.38279452 -5.42 <.0001 
> 65 years 3.147859 0.54721375 5.75 <.0001 
45-65 years - - - - 
Gender 
Males -0.185170 0.35308193 -0.52 0.6002 
Females - - - - 
Race 
Blacks 1.008868 0.46058275 2.19 0.0290 
Asians  -0.254178 1.25548987 -0.20 0.8397 
Multiple Races 0.754341 1.01934443 0.74 0.4597 
Whites - - - - 
Marital Status* 
Widowed -0.741 0.63211 -1.17 0.2417 
Divorced -1.6109 0.44247 -3.64 0.0003 
Separated -1.7505 0.89523 -1.96 0.0512 
Never married -2.7223 0.43057 -6.32 <.0001 
Married - - - - 
Education 
No education -0.2248 1.55815 -0.14 0.8854 
Elem/ Mid School 0.01862 0.65138 0.03 0.9772 
High school -0.0222 0.35052 -0.06 0.9496 
5+ years college 0.60689 0.58198 1.04 0.2976 
≤4 years college - - - - 
Employment Status* 
Employed 1.618264 0.41601700 3.89 0.0001 
Unemployed - - - - 
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Income a 
Low -0.181734 0.50670403 -0.36 0.7200 
High 0.756142 0.51285046 1.47 0.1411 
Middle class - - - - 
Overall Health Status* 
Excellent 18.376139 0.77668778 23.66 <.0001 
Very good 14.833277 0.64242942 23.09 <.0001 
Good 11.581959 0.59187438 19.57 <.0001 
Fair 6.417728 0.59524026 10.78 <.0001 
Poor - - - - 
Comorbidities 
Asthma 0.350122 0.52871868 0.66 0.5082 
Arthritis 0.170229 0.42819455 0.40 0.6912 
Diabetes 1.503815 0.76608830 1.96 0.0503 
High blood pressure 0.404819 0.65851149 0.61 0.5391 
None - - - - 
Number of comorbidities 
2 0.323815 1.13879645 0.28 0.7763 
≥ 3 - - - - 
Combinations of antidepressants*** 
SSRI-MA** -1.5584 1.35104 -1.15 0.2494 
SNRI-MA** -5.4855 3.90132 -1.41 0.1604 
SSRI-SNRI -2.0289 3.15032 -0.64 0.5199 
SSRI-TCA 2.20433 2.9153 0.76 0.45 
Other combinations -1.6377 2.51062 -0.65 0.5145 
None - - - - 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA** - Miscellaneous Agents 
*Significant predictors, ***-Significant at α=0.1   
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between 
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
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Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
No t – No therapy 
MA* - Miscellaneous Agents 
Both- Antidepressant and Psychotherapy both 
 
Figure 3: Distribution of PHQ-2 scores across depression therapy classes 
 
Table 9: Significant ANOVA results for PHQ-2 scores comparison across depression 
therapy classes 
Comparisons significant at the 0.05 level are indicated by ***. 
Therapy Class Difference 
Between 
Means 
Simultaneous 95% Confidence 
Limits 
 
5: Psyc - 1: SSRI 0.35053 0.02424 0.67681 *** 
0: No t* - 1: SSRI 0.14484 0.02447 0.26521 *** 
1: SSRI - 5: Psyc -0.35053 -0.67681 -0.02424 *** 
1: SSRI - 0: No t -0.14484 -0.26521 -0.02447 *** 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
No t* - No therapy 
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Table 10: Regression results for PHQ-2 Scores for combinations of antidepressants 
 
Parameter Estimate Standard Error t Value Pr > |t| 
Intercept* 2.694124 0.48879317 5.51 <.0001 
Age Groups* 
18-44 years 0.217255 0.07258875 2.99 0.0029 
> 65 years -0.400896 0.11087437 -3.62 0.0003 
45-65 years - - - - 
Gender 
Males 0.087150 0.06934299 1.26 0.2095 
Females - - - - 
Race* 
Blacks -0.183707 0.10973178 -1.67 0.0948 
Asians  -0.151575 0.29001387 -0.52 0.6015 
Multiple Races -0.035496 0.24603147 -0.14 0.8854 
Whites - - - - 
Marital Status* 
Widowed 0.02015 0.13274 0.15 0.8794 
Divorced 0.23396 0.08047 2.91 0.0038 
Separated 0.10532 0.21016 0.5 0.6165 
Never married 0.15652 0.08804 1.78 0.0762 
Married - - - - 
Education 
No education -0.1324 0.27974 -0.47 0.6362 
Elem/ Mid School -0.1372 0.16398 -0.84 0.4034 
High school 0.0792 0.07231 1.1 0.274 
5+ years college -0.1419 0.11152 -1.27 0.2039 
≤4 years college - - - - 
Employment Status* 
Employed -0.342392 0.08228428 -4.16 <.0001 
Unemployed - - - - 
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Income a 
Low 0.160173 0.10910055 1.47 0.1428 
High -0.073283 0.08796945 -0.83 0.4053 
Middle class - - - - 
Overall Health Status* 
Excellent -2.870641 0.15753074 -18.22 <.0001 
Very good -2.540560 0.15289902 -16.62 <.0001 
Good -1.976290 0.14120859 -14.00 <.0001 
Fair -0.989290 0.14615247 -6.77 <.0001 
Poor - - - - 
Comorbidities 
Asthma 0.023763 0.11088139 0.21 0.8304 
Arthritis 0.033420 0.08681256 0.38 0.7005 
Diabetes -0.011586 0.14908447 -0.08 0.9381 
High blood pressure 0.084496 0.10383440 0.81 0.4162 
None - - - - 
Number of comorbidities 
2 0.305076 0.36284854 0.84 0.4009 
≥ 3 - - - - 
Combinations of antidepressants 
SSRI-MA** -0.465199 0.36555129 -1.27 0.2039 
SNRI-MA** 0.553461 0.49684260 1.11 0.2659 
SSRI-SNRI 0.090573 0.36314474 0.25 0.8032 
SSRI-TCA -0.448151 0.80005073 -0.56 0.5757 
Other combinations -0.051863 0.20586987 -0.25 0.8012 
None - - - - 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -  
Norepinephrine Reuptake Inhibitor, TCA – Tricyclic antidepressants  
MA** - Miscellaneous Agents 
*Significant predictors 
a - Low defined as income <100% FPL (<$12,060), middle class defined as income between 
the range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
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Table 11: Multinomial regression results for depression frequency for combinations of 
antidepressants 
Predictor Depression frequency (OR, Confidence Intervals)a 
0: Not at all 1: Several Days 2: More Than Half 
the Days 
Age** 
18-44 years 0.656** 
(0.517, 0.833) 
0.836 
(0.653, 1.069) 
1.112 
(0.863, 1.434) 
> 65 years 2.000** 
(1.384, 2.889) 
1.361 
(0.963, 1.924) 
1.201 
(0.805, 1.793) 
45-65 years Reference Reference Reference 
Gender  
Males 0.866 
(0.702, 1.069) 
0.886 
(0.724, 1.085) 
1.048 
(0.828, 1.328) 
Females Reference Reference Reference 
Race ** 
Blacks 1.394** 
(1.029,1.889) 
1.111 
(0.842,1.467) 
              1.572** 
(1.167,2.119) 
Asians 1.055 
(0.557,2.001) 
1.188 
(0.661,2.138) 
0.839 
(0.357,1.972) 
Multiple races 1.187 
(0.580,2.432) 
1.166 
(0.632,2.151) 
1.427 
(0.746,2.731) 
Whites Reference Reference Reference 
Marital Status** 
Widowed 
 
  0.682 
(0.463,1.003) 
           0.786 
(0.542,1.140) 
0.775 
(0.503,1.193) 
Divorced 
 
 0.622** 
        (0.477,0.812) 
          0.698** 
      (0.545,0.894) 
0.921 
(0.701,1.208) 
Separated 
 
 0.531** 
      (0.318,0.887) 
0.709 
(0.438,1.150) 
1.031 
(0.599,1.775) 
Never Married 
 
0.574** 
      (0.422,0.782) 
           0.655** 
    (0.493,0.871) 
0.821 
(0.601,1.124) 
Married Reference Reference Reference 
Education** 
No education 
 
0.989 
(0.303,3.222) 
0.945 
(0.308,2.897) 
1.210 
(0.348,4.209) 
Elem/ Mid school 
 
0.660 
(0.431,1.011) 
  0.568** 
      (0.391,0.825) 
0.716 
(0.462,1.108) 
High school  
 
0.726** 
       (0.569,0.927) 
           0.722** 
      (0.572,0.912) 
0.796 
(0.615,1.030) 
5+ years college  1.127 
(0.700,1.813) 
0.989 
(0.625,1.565) 
0.733 
(0.407,1.320) 
≤ 4 years college Reference Reference Reference 
Employment Status** 
Employed 
 
1.847** 
(1.413, 2.415) 
1.599** 
(1.251, 2.045) 
1.430** 
(1.09, 1.895) 
Unemployed Reference Reference Reference 
Income b 
Low 0.752** 0.773 0.951 
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 (0.566,0.999) (0.595, 1.003) (0.722, 1.251) 
High 
 
1.147 
(0.786, 1.676) 
0.995 
(0.678, 1.461) 
0.947 
(0.608, 1.474) 
Middle class Reference Reference Reference 
Overall Health Status  
Excellent 119.049** 
(59.58, 237.87) 
11.451** 
(5.772, 22.717) 
1.613 
(0.703, 3.702) 
Very good 
 
69.674** 
(42.688, 113.720) 
12.815** 
(8.477, 19.372) 
2.610** 
(1.612, 4.228) 
Good 23.542** 
(15.703, 35.292) 
7.477** 
(5.520, 10.129) 
1.966** 
(1.402, 2.757) 
Fair 5.512** 
(3.724, 8.159) 
2.917** 
(2.204, 3.860) 
1.521** 
(1.116, 2.073) 
Poor Reference Reference Reference 
Comorbidities  
Asthma 1.111 
(0.803, 1.538) 
1.053 
(0.774, 1.432) 
0.877 
(0.626, 1.230) 
Arthritis 0.877 
(0.664, 1.158) 
0.976 
(0.752, 1.266) 
0.953 
(0.726, 1.252) 
Diabetes 1.330 
(0.794, 2.228) 
1.355 
(0.814, 2.255) 
1.042 
(0.585, 1.856) 
High blood pressure 1.082 
(0.745, 1.572) 
0.848 
(0.583, 1.233) 
1.158 
(0.733, 1.829) 
None Reference Reference Reference 
Number of Comorbidities  
2 0.712 
(0.310, 1.637) 
0.874 
(0.420, 1.819) 
0.682 
(0.312, 1.491) 
≥3 Reference Reference Reference 
Combinations of antidepressants** 
SSRI-MA** 1.072 
(0.351, 3.276) 
1.227 
(0.438, 3.435) 
0.673 
(0.193, 2.351) 
SNRI-MA** 0.288 
(0.040, 2.073) 
0.863 
(0.131, 5.687) 
0.285 
(0.021, 3.808) 
SSRI-SNRI 0.542 
(0.135, 2.177) 
0.723 
(0.192, 2.731) 
N/Ac 
SSRI-TCA 1.482 
(0.174, 12.650) 
0.304 
(0.032, 2.885) 
0.287 
(0.028, 2.940) 
Other combinations 0.951 
(0.258, 3.498) 
0.329 
(0.051,2.104) 
0.052** 
(0.004,0.622) 
None Reference Reference Reference 
Abbreviations: SSRI – Selective Serotonin Reuptake Inhibitors, SNRI – Serotonin -Norepinephrine 
Reuptake Inhibitor, TCA – Tricyclic antidepressants  
*MA = Miscellaneous Agents 
aThe reference class for depression frequency was 3: Nearly every day 
** - Significant results 
b - Low defined as income <100% FPL (<$12,060), middle class defined as income between the 
range of 100-400% FPL ($12,060-$48,240) and high defined as income over 400% FPL 
(>$48,240) 
c- N/A – Not applicable, since there were almost no patients in that group and the sample size for 
that cell was < 5, the OR obtained for that particular group were absurd 
